Archive for June, 2015

(KEYW) Strategic Executive Changes Prepare Company for Growth

HANOVER, Md., June 30, 2015  — Hexis Cyber Solutions, Inc. (Hexis), a wholly-owned subsidiary of The KEYW Holding Corporation (NASDAQ:KEYW), and a provider of advanced cybersecurity solutions for commercial companies and government agencies, today welcomes Jan Manning as the company’s Vice President of IT Operations. The company is also pleased to appoint Chris Carlson as its new Vice President of Product Management, HawkEye G. These organizational changes, coupled with strong industry demand for innovative cybersecurity solutions, help to position Hexis for growth and demonstrate the company’s commitment to innovation and customer success in combating sophisticated threats.

Jan Manning joins the Hexis team after having served as CIO for SafeNet-Gemalto, where she was responsible for defining and implementing corporate application and infrastructure standards across the company’s entire technology footprint. A security industry veteran, Manning will drive Hexis overall IT strategy, IT based services and ensure the company is well-positioned for expansion.

“Working in a field as fast-paced as IT security, I was eager to join a team willing to break industry boundaries and offer next-generation, innovative solutions like automated threat removal,” said Jan Manning, Vice President, Information Technology and Operations, Hexis Cyber Solutions. “This is an exciting time for Hexis as it emerges as a leader in the cybersecurity market. I am thrilled to be part of the team that will help drive the company forward, focusing on enhancing our internal infrastructure and processes to allow us to take advantage of new opportunities and serve a growing customer base.”

Hexis is equally pleased to announce that its former Senior Director of Product Management, Chris Carlson, has been promoted to Vice President of Product Management, HawkEye G. Having joined the Hexis team in September of 2014, Carlson’s talents as a security expert were exemplified by his leadership in the recent launch of HawkEye G 3.0, the company’s flagship solution. Carlson played a major role in the development of HawkEye G’s new ThreatSync™ capability for evidence-based detection and verification of unknown and known threats, and integration with popular third-party security technologies for increased threat intelligence.

“Given our current rate of success it’s clear that the time is right for a solution like HawkEye G that accelerates time to detection and removes advanced threats before damage is done,” said Chris Fedde, President, Hexis Cyber Solutions. “The addition of Jan to our team and Chris’ promotion will allow us to take Hexis to the next level. Their expertise and experience will help ensure we continue to execute in the way we need to build on our momentum and solidify our position as a leader in the cybersecurity market.”

About Hexis Cyber Solutions

Hexis Cyber Solutions, Inc. is a team of cybersecurity experts delivering solutions that enable organizations to defend against and remove cyber threats at machine speeds before they do damage. Hexis’ advanced security solutions use real-time endpoint sensors, network detection, and threat analytics to provide organizations with an intelligent and automated threat detection and response solution. Hexis’ solutions deliver improved visibility into the network and endpoints, threat verification, and automated threat removal capabilities for organizations of all sizes.

Hexis Cyber Solutions, Inc. is a wholly-owned subsidiary of The KEYW Holding Corporation (KEYW), based in Hanover, Maryland with engineering offices in Columbia, Maryland and San Mateo, California. Hexis’ solutions were developed leveraging KEYW’s expertise in supporting our nation’s cybersecurity missions. For more information contact Hexis Cyber Solutions, 7740 Milestone Parkway, Suite 400, Hanover, Maryland 21076; Phone 443-733-1900; Fax 443-733-1901; E-mail; or on the Web at

Follow Hexis on Twitter: @hexis_cyber

About KEYW

KEYW provides agile cyber superiority, cybersecurity, and geospatial intelligence solutions for U.S. Government intelligence and defense customers and commercial enterprises. We create our solutions by combining our services and expertise with hardware, software, and proprietary technology to meet our customers’ requirements. For more information contact KEYW Corporation, 7740 Milestone Parkway, Suite 400, Hanover, Maryland 21076; Phone 443-733-1600; Fax 443-733-1601; E-mail; or on the Web at

For Media Inquiries:
Nina Korfias - MSLGROUP

For Investor Relations:
Chris Donaghey - Hexis
Tuesday, June 30th, 2015 Uncategorized Comments Off on (KEYW) Strategic Executive Changes Prepare Company for Growth

(AMRS) Announces Total’s Decision to Proceed With Jet Fuel Joint Venture

EMERYVILLE, Calif., June 30, 2015  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has agreed on key business terms with Total Energies Nouvelles Activités USA (a wholly owned subsidiary of Total S.A.) (“Total”) for restructuring its fuels joint venture to open the way for proceeding with commercialization of its jet fuel technology over the coming years. Following the restructuring, Total would own 75% of the joint venture with Amyris.

In conjunction with this transaction, Amyris has also agreed on key business terms with Total and Temasek, another major stockholder of Amyris, under which, and as part of a plan to strengthen the balance sheet, these stockholders would exchange an aggregate of $138 million of convertible debt for Amyris common stock at a price of $2.30 per share, with an additional $37 million of outstanding convertible debt being restructured to eliminate Amyris’s repayment obligation at maturity and provide for mandatory conversion to Amyris common stock. The terms of the restructuring include provisions related to the note conversions for these participating stockholders, including to maintaining pro rata holdings. The closing of the exchange transactions would be subject to customary closing conditions, including any required Board of Directors or other internal approvals, and regulatory approvals or notices.

These joint venture and exchange transactions are subject to the execution of definitive agreements between Amyris and the parties, the terms of which may vary from those described above.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’ expectation of entering into agreements to restructure its fuels joint venture with Total to encompass the commercialization of jet fuel and agreements for the conversion of certain outstanding convertible debt into common stock through a pricing mechanism currently resulting in a price of approximately $2.30 per share and restructuring of certain other outstanding convertible debt) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks that Amyris, Total and Temasek will not be able to agree to final terms for the completion of the completed agreements and that required consents and approvals for the entry into these agreements may not be obtained, that consummation of the restructuring of the fuels joint venture and the conversion agreements will be subject to numerous conditions to be negotiated by the parties, certain of which are likely to be outside of Amyris’s control, as well as risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-Q filed on May 5, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris is a registered trademark of Amyris, Inc.

CONTACT: Peter DeNardo
         Director, Investor Relations and Corporate Communications
         Amyris, Inc.
         +1 (510) 740-7481
Tuesday, June 30th, 2015 Uncategorized Comments Off on (AMRS) Announces Total’s Decision to Proceed With Jet Fuel Joint Venture

(TLOG) Announces Update on MDS Clinical Program

MALVERN, Pa., June 30, 2015  — TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced preliminary data from the ongoing Phase 2A study of birinapant in combination with azacitidine in first line higher risk myelodysplastic syndromes (MDS). The study is being conducted as a precursor to the ongoing randomized Phase 2B study.

In this study, birinapant was administered, at 13 mg/m2 twice a week, three weeks out of four, during a four week cycle in combination with the approved dose of azacitidine. The primary assessment of efficacy was the response rate using the modified International Working Group criteria (Cheson 2006) at the end of cycle four. Of the nine patients who entered the study, six completed four cycles of therapy and underwent a repeat bone marrow assessment. Three patients experienced a complete response, one patient experienced a bone marrow complete response, one patient experienced a partial response and underwent a stem cell transplant and one patient had stable disease. Three patients discontinued the study prior to receiving four cycles of treatment. The regimen was generally well tolerated, the most common side effects being fatigue, neutropenia and thrombocytopenia.

“While acknowledging the small number of patients involved in the study, we find these data encouraging,” said Dr. Lesley Russell, TetraLogic’s Chief Medical Officer. “We plan to conduct an interim analysis of the ongoing randomized trial around the end of the year and look forward to reviewing those results.”

About TetraLogic Pharmaceuticals Corporation

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being evaluated for the treatment of solid and liquid tumors and certain intracellular pathogens.   SHAPE is being evaluated for the treatment of early-stage cutaneous T‑cell lymphoma.

Forward Looking Statements

Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic’s pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2015 and in our Form 10-Q filed with the SEC on May 14, 2015.  Any forward looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889-9900, x103
Tuesday, June 30th, 2015 Uncategorized Comments Off on (TLOG) Announces Update on MDS Clinical Program

(AST) Added To Russell Indexes

MENLO PARK, Calif., June 30, 2015  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® indexes following Russell Investments’ (“Russell”) reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. Each June, Russell completely rebalances its indexes, known as a reconstitution, to reflect market changes in the past year.

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. Approximately $5.7 trillion in assets are currently benchmarked to Russell indexes and more than $800 billion in assets are invested in products based on them. The most well-known index of the series is the Russell 2000®, a subset of the Russell 3000® Index that measures the performance of the small-cap segment of the U.S. equity market.

Russell determines membership for its equity indexes, which remains in place for one year, primarily by objective, market-capitalization rankings and style attributes. The Russell 3000® captures the 3,000 largest U.S. stocks as of the end of May of each year, ranking them by total market capitalization. The largest 1,000 companies in this ranking make up the Russell 1000® and the next largest 2,000 companies comprise the Russell 2000®. The Russell 3000® also serves as the U.S. component to the Russell Global Index. The Russell Microcap® consists of the smallest 1,000 securities in the small-cap Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company’s proprietary, industry leading platforms are based on its pluripotent stem cell and allogeneic dendritic cell technologies. Pluripotent stem cells are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines.  Additional information about Asterias can be found at


Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’ filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

Tuesday, June 30th, 2015 Uncategorized Comments Off on (AST) Added To Russell Indexes

(SGNL) Announces Master Service Agreement

CARLSBAD, Calif., June 30, 2015  — Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal’s proprietary MyPRS® genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.

Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA.  Under the agreement, MyPRS® will help inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.

Michael Cerio, SVP of Commercial Strategy and Business Development, commented, “This services agreement with a leading pharmaceutical company is a significant achievement for Signal, and validates the potential of our technology to impact therapy decisions in multiple myeloma. We believe this agreement demonstrates that the pharmaceutical industry recognizes the value of MyPRS® as part of the genetic testing armament in cancer. Developing a pipeline of pharmaceutical company relationships is a key objective for Signal, and we plan to pursue additional clinical trial service agreements with multiple clients as part of our overarching commercial strategy going forward.”

About Signal Genetics, Inc.

Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal’s mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.

Safe Harbor Statement

This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “may,” “will,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding our ability to achieve profitability and to penetrate the market opportunity that we believe exists for our prognostic genetic test. Such forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those discussed here, such as our ability to obtain adequate coverage and reimbursement for our tests from third party payors, our ability to obtain necessary regulatory clearances and approvals, the ability of our tests to keep pace with rapid advances in technology, medicine and science, and our ability to execute our marketing strategy and gain acceptance in the market, along with those other risks and uncertainties detailed in our SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date this release and we assume no obligation to update or revise these statements unless otherwise required by law.

         The Ruth Group
         David Burke
         Tel: 646-536-7009
Tuesday, June 30th, 2015 Uncategorized Comments Off on (SGNL) Announces Master Service Agreement

(SOFO) Expands its Mediasite Lecture Capture Deployment Campus-Wide

Australian university sees 100 percent growth in video creation and views, increased student satisfaction and dynamic student-faculty engagement

Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted global leader for video creation and management solutions, today announced Southern Cross University in Australia has expanded its Mediasite deployment campus-wide.

Through a major AV expansion project, the university added Mediasite to all classrooms across its three campuses so that every lecture could be recorded and available for students live and on-demand in their learning management system, Blackboard. The university also increased using My Mediasite Desktop Recorder for faculty and staff to create and share videos, lectures and assignments from any device and location.

Before the expansion, the university’s 4,025 Mediasite videos had garnered about 82,000 views. Now, there are 7,500 videos with 174,000 views, a 100 percent growth in a short amount of time.

“Mediasite has significantly extended our local and global reach, reduced our attrition rates and attracted and engaged more students by strengthening our distance and flexible learning offerings. Since every single lecture is provided online, students don’t need to be on campus, and the content is much more engaging than just written material,” said Tim Lane, Manager of Client Services and Security, Southern Cross University. “Engaging students is incredibly important, particularly in a very competitive tertiary sector in Australia.”

Almost half of the university’s 10,000 students study through distance education with a large percentage residing in the Asia-Pacific region. Because government funding to universities in Australia is linked to the number of students who graduate rather than enrollment figures, student attraction, engagement and retention is a major priority.

Not only has Mediasite solved that problem, but it’s also changed the way faculty teach. They’re producing videos to address a range of popular topics and are using Mediasite’s powerful analytics to keep track of student viewing habits and improve content and delivery.

“Faculty are increasingly editing lectures in Mediasite down to small five to 10 minute segments to maintain students’ attention span. Students simply love this way of teaching. There has been a dramatic increase in student viewing attention to the video lectures, and grades have increased since introducing Mediasite and My Mediasite into classrooms,” Lane said. “Before Mediasite, we didn’t have a competitive advantage. Now we do, and the world is at our fingertips.”

“For the 21st century student, online anytime instruction is a staple, not a luxury, and Mediasite lecture capture improves the learning experience,” said Gary Weis, Sonic Foundry CEO. “Southern Cross University has seen some impressive results from its lecture capture program, and we’re pleased to partner with the university as it grows its deployment to increase engagement and student achievement.”

The university won a Sonic Foundry Enterprise Video Award in April at the Mediasite User Conference, Unleash. Watch its nomination video here.

About Southern Cross University

SCU is an Australian public university with campuses on the North Coast of New South Wales, Australia and southern Gold Coast, Queensland, Australia.

About Sonic Foundry®, Inc.

Sonic Foundry (NASDAQ: SOFO) is the trusted global leader for video capture, management and webcasting solutions in education, business and government. The patented Mediasite Enterprise Video Platform transforms communications, training, education and events for more than 3,000 customers in over 60 countries.

© 2015 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

Sonic Foundry, Inc.
Nicole Wise, 608.237.8678

Monday, June 29th, 2015 Uncategorized Comments Off on (SOFO) Expands its Mediasite Lecture Capture Deployment Campus-Wide

(SHOS) Sears Hometown Opens New West Virginia Store in Hurricane

Local Retailer Offers Top Brand Home Appliances, Lawn and Garden Equipment, Tools, Mattresses, and More at Guaranteed Lowest Price

HURRICANE, W.Va., June 29, 2015  — Sears Hometown and Outlet Stores, Inc. (NASDAQ:SHOS) will open its newest West Virginia Sears Hometown Store on June 30th at 8 Putnam Village Drive in Hurricane.

The Hurricane location marks the 18th opening of a new Sears Hometown Store this year and the 26th opening of a new store across all of Sears Hometown and Outlet Stores formats. Unlike most retail concepts, Sears Hometown Stores combine the value, selection and services associated with larger retail stores but are owned and operated by a member of the local community.

“By providing customers with great products, exceptional customer service and a wonderful store experience, we’re filling a void in the Hurricane market,” said Mark Hagar, the owner of Sears Hometown in Hurricane. “We want to create the most convenient shopping experience for our community by combining in-store shopping and online-to-store pick-up giving them a one-stop resource for the products they want and need.”

This unique store format allows customers in small communities to have access to the great products and brands usually found only in Sears stores. For instance, the new Sears Hometown Store in Hurricane is the only place in town where customers can find an incredible selection of the top appliance brands such as Kenmore®, Maytag®, KitchenAid®, Whirlpool®, Bosch®, Frigidaire® and GE®, plus a large assortment of lawn and garden equipment, Craftsman® tools, fitness equipment, mattresses and more.

The Hurricane team is excited to provide customers with professional advice, exceptional service and real-time price checks to make sure they receive the guaranteed lowest price. For instance, if a product is not available in-stores, Sears Hometown Store associates can order customers any product from the entire merchandise selection offered by Sears, including apparel, footwear, jewelry and much more. Customers also have the option to order products online and pick them up in the store without a shipping charge. The Hurricane store also offers Sears Nationwide Service, Parts and Installation.

The Sears Hometown Store in Hurricane can be reached at (304) 757-2330 and is open Monday through Saturday from 9:30 a.m. to 7 p.m. and on Sunday from 11 a.m. to 5 p.m. To learn more about Sears Hometown Stores, visit

About Sears Hometown and Outlet Stores, Inc.

Sears Hometown and Outlet Stores, Inc. (NASDAQ:SHOS) is a national retailer primarily focused on selling home appliances, lawn and garden equipment, tools and hardware. As of May 2, 2015, Sears Hometown and Outlet Stores, Inc. and its dealers and franchisees operated 1,248 stores across all 50 states as well as in Puerto Rico and Bermuda. In addition to merchandise, Sears Hometown and Outlet Stores, Inc. provide consumers with access to a full suite of services, including home delivery, installation and extended service contracts.

Operating through two segments—the Sears Hometown and Hardware segment and the Sears Outlet segment—Sears Hometown and Outlet Stores, Inc. and its subsidiaries offer franchise and dealership opportunities focused on selling, as applicable, top brand home appliances, hardware, tools, lawn and garden equipment and outlet merchandise. For more information about Sears Hometown & Outlet Stores, Inc., visit To learn about the opportunity to own and operate a store format, visit

         Phone Number: 847-945-1300
         Email Address:
Monday, June 29th, 2015 Uncategorized Comments Off on (SHOS) Sears Hometown Opens New West Virginia Store in Hurricane

(CYCCP) & ManRos Announce Licensing & Supply Agreement

Novel CDK Inhibitor-Based Approach to Treat Cystic Fibrosis

DUNDEE, UK and ROSCOFF, France, June 29, 2015 — Cyclacel Ltd, a wholly owned subsidiary of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel”) and ManRos Therapeutics SA (“ManRos”) announced the execution of a collaboration, licensing and supply agreement for the exclusive development and commercialisation of Cyclacel’s oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (CF). Among other terms of the agreement ManRos licensed rights to Cyclacel’s proprietary clinical data to enable clinical development of seliciclib for cystic fibrosis indications. The agreement provides for Cyclacel supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to Cyclacel’s know-how to facilitate these trials. Cyclacel will receive an up-front payment, milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF. Financial details were not disclosed.

“Treatment of lung disease associated with CF represents a major unmet medical need, in particular, with regard to reducing dysregulated innate immunity, chronic infections, inflammation and subsequent lung injury,” said Dr. Laurent Meijer, President of ManRos. “Seliciclib is a well-studied, orally-available, investigational medicinal product. We have shown that seliciclib acts through multiple mechanisms and may confer therapeutic benefits to CF patients. With this agreement we are leveraging Cyclacel’s extensive clinical experience with seliciclib in hundreds of cancer patients to offer patients with CF a differentiated treatment alternative. Following receipt of regulatory authorisations, we expect that proof-of-concept clinical trials in CF patients will begin in the near term.”

“The CDK field is experiencing a resurgence and CDK inhibitors are receiving a lot of attention as novel treatments in oncology and other proliferative diseases,” said Spiro Rombotis, Chief Executive Officer of Cyclacel. “Like Cyclacel, the founders of ManRos have been studying CDK inhibitors for many years and will be evaluating an innovative application of a CDK inhibitor to potentially help patients with CF. The agreement with ManRos illustrates our commitment to generate value from our portfolio of CDK inhibitors and deliver on our science-driven business strategy.”

Seliciclib Mechanism of Action in CF

Patients with CF suffer from extensive inflammatory and chronic infectious injury to the lung airway. It was recently recognized that immune system defects, and in particular macrophage function, play a key role in disease initiation. It has also been reported that impairment of the CFTR gene is associated with modification of macrophage function resulting in reduced bactericidal activity (Di et al., 2006) and disease progression. ManRos and academic collaborators have discovered that seliciclib may restore the defective bactericidal activity of macrophages in CF (publication pending). They have also discovered that seliciclib may have “corrector” activity in the most prevalent CF mutation, F508del (Norez 2014). Separately, independent investigators have demonstrated in model systems that seliciclib has anti-inflammatory properties which may also help reduce inflammatory injury in patients with CF (Rossi et al., 2006; Moriceau 2010).

About Cystic Fibrosis

Cystic Fibrosis (CF) is a life-threatening inherited genetic disease that primarily affects the lungs and digestive system.  An estimated 70,000 children and adults worldwide (of which an estimated 30,000 in the United States) suffer from CF. In CF patients, a defective gene (CFTR) and its protein product cause the body to produce unusually thick, sticky mucus that clogs the lungs, leads to life-threatening lung infections, obstructs the pancreas and stops natural enzymes from helping the body break down food and absorb vital nutrients. There are more than 1,900 known mutations of the CFTR gene. The most common mutation is F508del and disrupts the function of many organs in the body, most notably the lungs, by perturbing salt and water transport across epithelial surfaces.

About seliciclib (also known as R-roscovitine, CYC202)

Seliciclib is an orally-available CDK2/9 inhibitor. It has been evaluated to date in approximately 450 patients with various cancers. Seliciclib is currently being explored in combination with Cyclacel’s sapacitabine in patients with advanced solid tumors as an all oral regimen.

About Cyclacel

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel’s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel’s pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor, with potential utility in both hematological malignancies and solid tumors. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit for more information.

About ManRos

ManRos is a biotechnology company founded by Dr. Laurent Meijer (a former CNRS research director) and Dr. Hervé Galons (Professor of Organic Chemistry at the University Paris-Descartes). Located in Roscoff (Brittany, France), ManRos aims at developing, optimizing and bringing to clinical trials a small selection of specific kinase inhibitors. Its pipeline comprises (1) R-roscovitine (for chronically infected cystic fibrosis patients; phase 2a expected to begin in the near future pending regulatory approval), (2) a family of kinase inhibitors (for autosomal dominant polycystic kidney disease (ADPKD); preclinical stage) and (3) Leucettines, a marine natural product derived alkaloid (for the treatment of cognitive defects in Down syndrome and Alzheimer’s disease patients; preclinical stage).


Di, A. et al., 2006. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8, 933-944.

Moriceau, S. et al., 2010. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. J. Innate Immun. 2, 260-266.

Norez, C. et al., 2014. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831-4849.

Rossi, A.G. et al., 2006. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12, 1056-1064. Erratum in: Nat. Med. 12, 1434.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

© Copyright 2015 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

CONTACT: Contacts for Cyclacel Pharmaceuticals, Inc.

         Company: Paul McBarron,
         (908) 517-7330,
         Investor Relations: Russo Partners LLC, Robert Flamm,
         (212) 845-4226,

         Contacts for ManRos Therapeutics
         Laurent Meijer,
Monday, June 29th, 2015 Uncategorized Comments Off on (CYCCP) & ManRos Announce Licensing & Supply Agreement

(ASBI) & (FRME) Signing of a Definitive Merger Agreement

First Merchants Corporation (NASDAQ: FRME) and Ameriana Bancorp (NASDAQ: ASBI) today announced they have executed a definitive agreement whereby Ameriana Bancorp will merge with and into First Merchants Corporation, and its wholly owned bank subsidiary, Ameriana Bank, will merge with and into First Merchants Bank, NA.

The merger agreement provides that shareholders of Ameriana Bancorp will have the right to exchange each Ameriana Bancorp common share held for 0.9037 shares of First Merchants’ common stock. Based on the closing price of First Merchants’ common stock on June 26, 2015 of $25.13, the transaction value is approximately $68.8 million, with an implied price per share of Ameriana Bancorp common stock of $22.71.

The transaction is expected to be completed in the fourth quarter of 2015, subject to the approval of Ameriana Bancorp shareholders, regulatory approvals, and other customary closing conditions. The combined financial institutions, which will do business as First Merchants Bank, expect to complete the integration during the second quarter of 2016.

Ameriana Bancorp had assets of approximately $483 million, loans of $325 million and deposits of $391 million as of March 31, 2015. Based upon current financials, First Merchants and Ameriana Bancorp will have combined assets of $6.4 billion and will remain the second largest financial holding company headquartered in Indiana. The combined company will have 126 banking offices in twenty-seven Indiana counties, as well as two counties in both Ohio and Illinois.

Michael C. Rechin, President and Chief Executive Officer of First Merchants, said, “Like First Merchants, Ameriana Bank has a deep-rooted commitment to community banking and we are excited to welcome Ameriana to the First Merchants family. The addition of Ameriana Bank supports our goal of becoming a more efficient, higher performing company. With the addition of significant deposits in Henry and Madison counties, First Merchants will hold the lead market share position. Our partnership will add new neighboring communities of Greenfield, New Palestine, New Castle, Knightstown and Morristown. The merger will also add five locations to our thirteen banking centers in Hamilton County, the fastest growing Indiana market.”

Rechin also added, “Management expects this combination to be mutually beneficial to First Merchants and Ameriana Bancorp shareholders. We anticipate earnings per share accretion in the first full year of combination and beyond through identified operating efficiencies and branch overlap of approximately fifty-five percent, resulting in a tangible book value earn-back of four years.”

Ameriana Bank, led by Chief Executive Officer, Jerome J. Gassen, has served the banking needs of Central Indiana customers as competitors of First Merchants for many years. Mr. Gassen stated, “We are excited about the opportunity to become part of the First Merchants family, and we believe First Merchants was the best choice for our collective stakeholders. First Merchants’ size, broad array of commercial and wealth management products, banking expertise and strong capital position offer us the ability to further capitalize on opportunities in Indianapolis, while continuing to offer exceptional customer service throughout Central Indiana. First Merchants will build on our shared dedication to community involvement and service excellence, as well as offer larger commercial credits, which drives greater economic and community development efforts.”

First Merchants was assisted in the transaction by Keefe, Bruyette & Woods, Inc., and Bingham Greenebaum Doll LLP served as legal counsel.

River Branch Capital advised Ameriana Bancorp’s board of directors in this transaction, and Kilpatrick Townsend & Stockton LLP served as legal advisor to Ameriana Bancorp.


First Merchants Corporation will conduct its Second Quarter 2015 Earnings conference call and web cast to discuss its Second Quarter Earnings and the pending acquisition of Ameriana Bancorp at 2:30 p.m. (ET) on Thursday, July 23, 2015.

To participate, dial (Toll Free) 877-507-0578 and reference First Merchants Corporation’s second quarter earnings. International callers please call +1 412-317-1073. To access a replay of the call, US participants should dial (Toll Free) 877-344-7529 or for International participants, dial +1 412-317-0088. The replay passcode is 10068128.

In order to view the web cast and presentation slides, please go to during the time of the call. A replay of the call will be available until July 23, 2016.


Communications in this press release do not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval. The proposed merger will be submitted to Ameriana Bancorp shareholders for their consideration. In connection with the proposed merger, First Merchants will file with the SEC a Registration Statement on Form S-4 that will include a Proxy Statement for Ameriana Bancorp and a Prospectus of First Merchants, as well as other relevant documents concerning the proposed transaction. SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING PROXY STATEMENT/PROSPECTUS REGARDING THE MERGER WHEN THEY BECOME AVAILABLE, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION. Once filed, you may obtain a free copy of the Proxy Statement/Prospectus, when it becomes available, as well as other filings containing information about First Merchants at the SEC’s Web Site ( You may also obtain these documents, free of charge, by accessing First Merchants’ Web site ( under the tab “Investors,” then under the heading “Financial Information,” and finally under the link “SEC Filings.”

Ameriana Bancorp and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Ameriana Bancorp in connection with the proposed Merger. Information about the directors and executive officers of First Merchants is set forth in the proxy statement for First Merchants’ 2015 annual meeting of stockholders, as filed with the SEC on a Schedule 14A on March 25, 2015. Information about the directors and executive officers of Ameriana Bancorp is set forth in the proxy statement for Ameriana Bancorp’s 2015 annual meeting of stockholders, as filed with the SEC on a Schedule 14A on April 17, 2015. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the Proxy Statement/Prospectus regarding the proposed merger when they become available. Free copies of this document may be obtained as described in the preceding paragraph.


This press release and the related conference call contain forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can often, but not always, be identified by the use of words like “believe”, “continue”, “pattern”, “estimate”, “project”, “intend”, “anticipate”, “expect” and similar expressions or future or conditional verbs such as “will”, would”, “should”, “could”, “might”, “can”, “may”, or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected timing and benefits of the proposed merger (the “Merger”) between First Merchants Corporation (“First Merchants”) and Ameriana Bancorp (“Ameriana Bancorp”), including future financial and operating results, cost savings, enhanced revenues, and accretion/dilution to reported earnings that may be realized from the Merger, as well as other statements of expectations regarding the Merger, and other statements of First Merchants’ goals, intentions and expectations; statements regarding First Merchants’ business plan and growth strategies; statements regarding the asset quality of First Merchants’ loan and investment portfolios; and estimates of First Merchants’ risks and future costs and benefits, whether with respect to the Merger or otherwise.

These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things: the risk that the businesses of the First Merchants and Ameriana Bancorp will not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; expected revenue synergies and cost savings from the Merger may not be fully realized or realized within the expected time frame; revenues following the Merger may be lower than expected; customer and employee relationships and business operations may be disrupted by the Merger; the ability to obtain required regulatory and shareholder approvals, and the ability to complete the Merger on the expected timeframe; possible changes in economic and business conditions; the existence or exacerbation of general geopolitical instability and uncertainty; the ability of First Merchants to integrate recent acquisitions and attract new customers; possible changes in monetary and fiscal policies, and laws and regulations; the effects of easing restrictions on participants in the financial services industry; the cost and other effects of legal and administrative cases; possible changes in the creditworthiness of customers and the possible impairment of collectability of loans; fluctuations in market rates of interest; competitive factors in the banking industry; changes in the banking legislation or regulatory requirements of federal and state agencies applicable to bank holding companies and banks like First Merchants’ affiliate bank; continued availability of earnings and excess capital sufficient for the lawful and prudent declaration of dividends; changes in market, economic, operational, liquidity, credit and interest rate risks associated with First Merchants’ business; and other risks and factors identified in each of First Merchants’ and Ameriana Bancorp’s filings with the Securities and Exchange Commission. Neither First Merchants nor Ameriana Bancorp undertakes any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this presentation or press release. In addition, First Merchants’ and Ameriana Bancorp’s past results of operations do not necessarily indicate either of their anticipated future results, whether the Merger is effectuated or not.

First Merchants Corporation
David L. Ortega, First Vice President/Director of Investor Relations, 765-378-8937
Ameriana Bancorp
Jerome J. Gassen, Chief Executive Officer, 765-521-7502

Monday, June 29th, 2015 Uncategorized Comments Off on (ASBI) & (FRME) Signing of a Definitive Merger Agreement

(JUNO) FDA Acceptance of IND Application for JCAR017 in Lymphoma

SEATTLE, June 29, 2015 (GLOBE NEWSWIRE) — Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s investigational new drug (IND) application for JCAR017 for patients with relapsed/refractory (r/r) B cell non-Hodgkin lymphoma, or NHL. JCAR017 is a chimeric antigen receptor (CAR) T cell product candidate targeting CD19, a protein expressed on the surface of most B cell leukemias and lymphomas.

The IND enables Juno to initiate a multi-center Phase I trial exploring JCAR017 for r/r NHL, scheduled to begin in 2015, with the potential to advance to a registration trial in 2016.

“Based on the encouraging results of JCAR017 in pediatric acute lymphoblastic leukemia, we are excited to begin investigating this product candidate in non-Hodgkin lymphoma,” said Mark Frohlich, M.D., Juno EVP of development and portfolio strategy. “FDA acceptance of the JCAR017 IND for this multi-institutional study is an important milestone for Juno. Together with our planned fully-human CD19 CAR-T cell trial, combination study with AstraZeneca’s anti-PDL-1 antibody, and ongoing translational clinical trial with JCAR014, it will provide important biologic insights that will inform our future strategies.”

In collaboration with Seattle Children’s Research Institute, Juno continues to investigate JCAR017 in pediatric patients with r/r acute lymphoblastic leukemia (ALL). Results of a Phase I study to date demonstrated 91 percent of patients achieved a complete remission, all of which were documented by flow cytometry. Adverse events were consistent with what has been previously reported. The results were presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia.

About Juno’s Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) Technologies

Juno’s chimeric antigen receptor (CAR) and T cell receptor technologies (TCR) genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell.

About Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. Juno’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute, and The National Cancer Institute.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding possible studies and other clinical development activities with respect to our product candidates, as well as the possible timing of such studies and activities, and insights and strategies related to them. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno’s product development activities and clinical trials, and Juno’s ability to finance these activities and trials; Juno’s ability to obtain regulatory approval for and to commercialize its product candidates; Juno’s ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno’s competitors with respect to competing treatments and technologies; Juno’s dependence on third-party collaborators and other contractors in Juno’s research and development activities, including for the conduct of clinical trials and the manufacture of Juno’s product candidates; Juno’s ability to effectively integrate the acquired technologies and employees into Juno’s operations and strategy and to realize the intended benefits of the transaction; Juno’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno’s business in general, see Juno’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2015 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations:
         Audrey Gross, W2O Group

         Julie Normart, W2O Group
Monday, June 29th, 2015 Uncategorized Comments Off on (JUNO) FDA Acceptance of IND Application for JCAR017 in Lymphoma

(NETE) Pending Acquisition PayOnline Inks Premium Dating Networks Deal

Minimum Processing Commitment of $300 Million in Transactions Over 3 Years

MIAMI, FL–(Jun 29, 2015) – Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”) today announced signing by PayOnline of a new 3-year contract to process transactions for certain international dating networks, including AnastasiaDate, AmoLatina and AsianDate.

The social networks receive over 150 million online visitors annually and have over 4 million registered users that spend over 360 million hours on the sites per year.

Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of Net Element’s acquisition of the company.

The contract with the majority owner of the dating networks, Social Discovery Ventures (“SDV”), provides for minimum net revenues to Net Element in the amount of $1.2 million over 3 years and a minimum transaction processing commitment of $300 million.

The contract underscores Net Element’s advantage as a global payments-as-a-service platform that facilitates cross-border transactions yet on-boards through a single interface.

SDV’s dating networks will use PayOnline’s state-of-the-art global online payments gateway and fraud-management tools to manage its international online transaction processing.

“The millions of international users on our premium dating networks require a reliable service able to process high volume, cross-border transactions using all forms of payments,” commented Anthony Volpe, Social Discovery Ventures chief marketing officer. “We selected Net Element because they met that need.”

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” commented Oleg Firer, Net Element CEO. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

About Net Element
Net Element, Inc.
(NASDAQ: NETE) operates a payments-as-a-service platform for small to medium enterprise (“SME”) in the US, Russian Federation and other international markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, India and Latin America. It maintains offices in Miami, FL and in Russia. Further information is available at

About Social Discovery Ventures

Social Discovery Ventures is the international umbrella brand for group of technology and software engineering companies, which provide platforms for social discovery, personal development, and online entertainment. SDV invests into, develops and supports a range of B2C Internet projects and brands under the framework of social discovery.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether the Company’s pending acquisition of PayOnline will be finalized, whether the contemplated minimum projected net revenues and minimum transaction processing commitment resulting from the referenced processing contract will materialize, whether Net Element can secure any additional financing and if such additional financing will be adequate to meet the Company’s objectives. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Media Contact:
Net Element, Inc.
(786) 923-0502

Monday, June 29th, 2015 Uncategorized Comments Off on (NETE) Pending Acquisition PayOnline Inks Premium Dating Networks Deal

(JRVR) A.M. Best Assigns Rating, Affirms Ratings of Its Subsidiaries

A.M. Best has assigned an issuer credit rating (ICR) of bbb- to James River Group Holdings, Ltd. (Holdings) [NASDAQ:JRVR]. The outlook assigned to the rating is positive. Concurrently, A.M. Best has affirmed the financial strength rating (FSR) of A- (Excellent) and the ICR of “a-” of JRG Reinsurance Company, Ltd. (JRG Re) and its U.S.-based insurance affiliates. The outlook for both ratings is positive. Holdings and JRG Re are both domiciled in Hamilton, Bermuda, and the U.S. subsidiaries are based in Richmond, VA and Raleigh, NC. (See below for a detailed listing of the companies.)

The ratings reflect JRG Re’s solid business profile and strategy execution under its experienced management team and its strong consolidated capitalization. This includes potential earnings from the company’s efforts to write third-party working layer reinsurance business from U.S.-based specialty insurers and supplementing the business that is derived from significant quota share reinsurance agreements with its onshore affiliates. These positive rating factors are partially offset by the challenges presented by a competitive casualty reinsurance market, as well as by results from the not- too- distant past that had shown weakness in underwriting results from workers’ compensation and the assumed crop reinsurance losses.

JRG Re has increased policyholder surplus by 28% to $386 million in 2014 from $301 million in 2010, net of a $50 million dividend paid prior to Holdings’ successful initial public offering in December 2014. The companies’ consolidated combined ratios of 94 and 91 in 2014 and 2013, respectively, reflect significant and, in A.M Best’s view, sustainable improvements over the 2012 and 2011 ratios of 107 and 104, respectively. Improved underwriting results reflect the impact of the company’s underwriting discipline, most notably in pricing increases and the termination of a number of unprofitable agency relationships, in addition to the exit from the crop business at the end of 2012.

JRG Re targets small to medium-sized specialty companies and maintains a diversified reinsurance portfolio weighted toward short- to intermediate-tail casualty business. The balance of its written premium has historically been derived from the net retained property/casualty exposures of its onshore affiliates. Effective Jan. 1, 2013, all of its U.S. affiliates participate in an intercompany pooling agreement, retaining 30% of net business with 70% ceded to JRG Re.

The positive outlook reflects the improvement in underwriting results under the management team assembled at JRG Re, as well as its solid risk-adjusted capital. JRG Re’s results have generally improved as reflected in its combined ratios due to strong and continuing net favorable reserve development. The company’s management teams and its U.S. operations have taken steps to improve pricing and profitability in growing its excess and supply lines segment and, to a lesser extent, its Specialty Admitted Insurance segment. Management has focused on further growth and improving operating performance in these two segments while opportunistically writing third-party reinsurance as fewer opportunities in the segment meet its risk appetite due to heavy competition from excess capital in the market for these risks.

Positive rating actions could occur if JRG Re and its U.S. operations continue to demonstrate improvement in underwriting results across its segments and by improving capital adequacy of JRG Re while preserving the capital adequacy of the U.S. operating companies. Conversely, negative rating actions could occur with materially weaker underwriting results in any one segment (e.g. workers’ compensation), significant weakening of capital adequacy as measured by Best’s Capital Adequacy Ratio (BCAR) that does not support the rating, or covenant defaults on its revolving credit facility.

The U.S. affiliates’ ratings are directly correlated to the ratings of JRG Re and receive full rating enhancement due to the explicit and implicit support provided by JRG Re.

The FSRs of A- (Excellent) and the ICRs of “a-” have been affirmed for JRG Reinsurance Company, Ltd. and its following affiliates:

  • Falls Lake General Insurance Company
  • Falls Lake National Insurance Company
  • James River Insurance Company
  • James River Casualty Company
  • Stonewood Insurance Company

This press release relates to rating(s) that have been published on A.M. Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please visit A.M. Best’s Ratings & Criteria Center.

A.M. Best Company is the world’s oldest and most authoritative insurance rating and information source. For more information, visit

Copyright © 2015 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

A.M. Best Company, Inc.
Dan Teclaw, 908-439-2200, ext. 5394
Senior Financial Analyst
Henry Witmer, 908-439-2200, ext. 5097
Assistant Vice President
Christopher Sharkey, 908-439-2200, ext. 5159
Manager, Public Relations
Jim Peavy, 908-439-2200, ext. 5644
Assistant Vice President, Public Relations

Friday, June 26th, 2015 Uncategorized Comments Off on (JRVR) A.M. Best Assigns Rating, Affirms Ratings of Its Subsidiaries

(LPLA) Retirement Plan Services & LPL Financial’s Employee Advice Solution

Tool helps achieve shared plan and participant goals of successful retirement outcomes

BOSTON, June 26, 2015  — John Hancock Retirement Plan Services (JHRPS) announced today it is supporting the use of LPL Financial’s Employee Advice Solution (EAS), a tool available within LPL’s Worksite Financial Solutions platform. JHRPS will support the tool administratively for its mutual Total Retirement Solutions (TRS) clients who have contracted with LPL for access to the service and directed JHRPS to provide that administrative support. Plan sponsors and participants served by LPL Financial advisors and JHRPS on the TRS platform now have access to the EAS tool.

Launched by LPL in 2014, the EAS tool enables the delivery of custom-tailored participant advice through an online service that collects information about a participant’s financial picture. Based on that information, participants can elect to receive personalized retirement advice or manage their accounts on their own. They can also elect to receive advice all the way through retirement.

LPL’s Worksite Financial Solutions is a website platform that provides financial education and a customized planning tool to enable participants to engage with a financial advisor directly—either face to face, online, or over the phone—in order to receive personal financial guidance based on their unique situation. The platform is fully integrated with LPL’s reporting and monitoring tools for plan advisors.

JHRPS provides a daily participant-level data feed when requested by plan sponsors, enabling LPL advisors to provide tailored financial advice and facilitate a closer relationship between advisors and plan participants.

“We believe in the value of advice to the individual. Our robust and flexible recordkeeping platform enables us to facilitate solutions such as Worksite Financial Solutions between our plan sponsors and LPL advisors,” said Patrick Murphy, President of John Hancock Retirement Plan Services.  “Access to comprehensive financial advice, beyond the 401(k), is vitally important to drive better outcomes for our participants.”

“This offering reflects both our long-standing partnership with LPL Financial and our shared goal of providing resources that make a difference in helping participants achieve successful retirement outcomes,” said George Revoir, Vice President of Distribution at John Hancock Retirement Plan Services. “This tool and our administrative support together will help financial advisors in their work with plan sponsors.”

Kathleen Kelly and the team at Compass Financial Partners, headquartered in Greensboro, N.C., are the first retirement plan advisor firm to engage a retirement plan to adopt EAS with a client at John Hancock.  As founding and managing partners, Ms. Kelly and George Hoyle specialize in the areas of retirement plan consulting and investment advisory services for qualified retirement plans and executive benefit planning. Compass Financial Partners is also the recipient of the 2014 NAPA 401(k) Advisor Leadership Award, which recognized the team’s contributions that exemplify leadership, experience, and expertise in the retirement plan industry.

David Reich, executive vice president and head of LPL’s Retirement Partners said, “We are extremely proud to work with Kathleen, George, and the team at Compass, and we value their support of the Worksite Financial Solutions platform, which we believe puts the power of technology to work for advisors and enables plan participants to receive the personalized advice they need in order to prepare for the landscape ahead with confidence. We are also honored that John Hancock recognizes the importance of this vision, and we look forward to working with them and all of our retirement-plan focused advisors to move the industry forward.”

The LPL Retirement Partners’ Employee Advice Solution (EAS) is offered through Morningstar Associates, LLC, which is solely responsible for its administration.  Morningstar Associates, LLC is a registered investment advisor and wholly owned subsidiary of the global research firm Morningstar, Inc. Morningstar has no affiliation with John Hancock. Neither John Hancock nor its affiliates provide financial, legal, or tax advice. John Hancock is not affiliated with LPL Financial Retirement Partners or with Compass Financial Partners, and does not endorse any of their products and/or services.

About John Hancock Financial and Manulife
John Hancock Financial is a division of Manulife, a leading Canada-based financial services group with principal operations in Asia, Canada and the United States. Operating as Manulife in Canada and Asia, and primarily as John Hancock in the United States, our group of companies offers clients a diverse range of financial protection products and wealth management services through its extensive network of employees, agents and distribution partners.  Assets under management by Manulife and its subsidiaries were C$821 billion (US$648 billion) as at March 31, 2015. Manulife Financial Corporation trades as ‘MFC’ on the TSX, NYSE and PSA, and under ‘945’ on the SEHK. Manulife can be found on the Internet at

The John Hancock unit, through its insurance companies, comprises one of the largest life insurers in the United States. John Hancock offers and administers a broad range of financial products, including life insurance, annuities, investments, 401(k) plans, long-term care insurance, college savings, and other forms of business insurance. Additional information about John Hancock may be found at

About LPL Financial
LPL Financial, a wholly owned subsidiary of LPL Financial Holdings Inc. (NASDAQ: LPLA), is a leader in the financial advice market and serves $485 billion in retail assets. The Company provides proprietary technology, comprehensive clearing and compliance services, practice management programs and training, and independent research to more than 14,000 independent financial advisors and over 700 banks and credit unions. LPL Financial is the nation’s largest independent broker-dealer since 1996 (based on total revenues, Financial Planning magazine, June 1996-2015), is one of the fastest growing RIA custodians with $105 billion in retail assets served, as of Dec. 31, 2014, and acts as an independent consultant to over an estimated 40,000 retirement plans with an estimated $120 billion in retirement plan assets served, as of March 31, 2015. In addition, LPL Financial supports approximately 4,300 financial advisors licensed with insurance companies by providing customized clearing, advisory platforms, and technology solutions. LPL Financial and its affiliates have 3,352 employees with primary offices in Boston, Charlotte, and San Diego. For more information, please visit Representatives of Compass Financial Partners are registered representatives of LPL Financial.

Securities and Advisory Services offered through LPL Financial. A Registered Investment Advisor, Member FINRA/SIPC

John Hancock Life Insurance Company (U.S.A.), John Hancock Life Insurance Company of New York and John Hancock Retirement Plan Services, LLC are collectively referred to as “John Hancock”.

John Hancock Retirement Plan Services, LLC offers service programs for retirement plans through which a sponsor or administrator of a plan may invest in mutual funds, ETFs, guaranteed products and collective investment trusts on behalf of plan participants. John Hancock Trust Company, LLC provides trust and custodial services to such plans. Securities products, when offered, may be offered through John Hancock Distributors LLC or NYLIFE Distributors LLC, as applicable, member FINRA/SIPC. Retirement plan sponsors may be able to select the option to offer the On Target investment advisory program to participants; services relating to this program are detailed in the applicable investment advisory agreement. Mutual funds, ETFs, guaranteed products and collective investment trusts available on the respective investment platform have not been individually selected by John Hancock Retirement Plan Services LLC, or any of its service providers.

Both John Hancock Life Insurance Company (U.S.A.) and John Hancock Life Insurance Company of New York do business under certain instances using the John Hancock Retirement Plan Services name. Group annuity contracts are issued by: John Hancock Life Insurance Company (U.S.A.), Boston, MA 02210 (not licensed in New York) and John Hancock Life Insurance Company of New York, Valhalla, NY 10595. The Investment Management Services Division of John Hancock provides investment information relating to the group annuity contract.

Plan administrative services may be provided by John Hancock Retirement Plan Services, LLC or a plan consultant selected by the Plan.


Friday, June 26th, 2015 Uncategorized Comments Off on (LPLA) Retirement Plan Services & LPL Financial’s Employee Advice Solution

(DBVT) Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer

DBV Technologies Proudly Welcomes

Dr. Hugh Sampson as Chief Scientific Officer

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the appointment of Dr. Hugh Sampson as Chief Scientific Officer (CSO). In this new role and in partnership with Dr. Dupont, chairman of the Company’s Scientific Advisory Board, Dr. Sampson will lead DBV’s research team, pursuing new Viaskin® applications for the treatment of food allergies, while also supporting the Company’s clinical development teams. Dr. Sampson’s appointment as CSO will become effective on November 1, 2015. Dr. Sampson will also continue serving as an advisor to the Company, as well as Director of the Research Center at the Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies, said: “Today marks a very important day for us. One of the world leaders in medical research in food allergy and immunology is joining our leadership team, and we are honored to welcome him to DBV. We believe that Hugh’s vision and unique experience will bring a lot of value as we seek to expand our platform in the coming years. By joining forces, we hope to make great strides both in research and clinical development. We share the same commitment to innovation and the same ambition to change the lives of millions of food allergic patients.”

Dr. Hugh Sampson, Chief Scientific Officer, said: “I am very excited to join the DBV team and look forward to exploring the potential of this innovative platform. In my short tenure as a member of the DBV Scientific Advisory Board, I have been very impressed with the dedication and energy of everyone at DBV and their desire to understand the basic science underlying this immunotherapeutic approach, which has the potential to benefit millions of food allergic patients.

Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson’s research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of food-induced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the National Institutes of Health (NIH) and private foundations. He is the Principal Investigator of the NIH-sponsored Consortium of Food Allergy Research (CoFAR). He is also former President of the American Academy of Allergy Asthma and Immunology (AAAAI).

About DBV Technologies 

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:

Forward Looking Statements

This press release contains forward-looking statements forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties.  The Company’s product candidates have not been approved for sale in any jurisdiction.  Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results.  A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts
Nathalie Donne
Director, Corporate Communication & Business Development
Tél. : +33(0)1 55 42 78 72
Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tél. : +1 917-346-3447
DBV Technologies Media Contacts US & Europe 
Marion Janic
Rooney & Associates
Tél. : +1-212-223-4017
Caroline Carmagnol
Alize RP – Relation Presse
Tél. : +33(0)6 64 18 99


Friday, June 26th, 2015 Uncategorized Comments Off on (DBVT) Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer

(PRQR) Enrollment Started in Global Phase 1b Cystic Fibrosis Study of QR-010

LEIDEN, the Netherlands, June 26, 2015  — ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that enrollment has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, a novel investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation.

“We are proud to announce that our first clinical study of QR-010 is now open and actively enrolling,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “Since the foundation of the company 3 years ago our team has worked very hard towards this step in the development of a therapy for CF, and we are excited to have reached this important milestone.”

“QR-010 is an innovative approach to target the underlying defect of CF. We are very pleased to participate in the first clinical trial for this novel compound,” said Professor Stuart Elborn of Queen’s University Belfast and immediate past-President of the European Cystic Fibrosis Society.

PQ-010-001 is a Phase 1b randomized, double-blind, placebo-controlled, 28-day study to be conducted in 20 centers worldwide. This first study will evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of inhaled QR-010 in 64 CF patients carrying two copies (homozygotes) of the DF508 mutation. As exploratory efficacy endpoints, this study will also assess sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by FEV1. In this study, QR-010 will be administered through inhalation for up to three times a week for a maximum period of four weeks. This Phase 1b trial will be conducted in parallel with a proof-of-concept Nasal Potential Difference (NPD) study that will begin enrollment of 16 CF patients that are either homo- or heterozygous for the DF508 mutation in Q3 of this year.

“The Phase 1b study and the NPD proof-of-concept study will provide a strong, early signal as to the therapeutic potential of QR-010,” said Noreen R. Henig, MD, Chief Development Officer of ProQR.

About CF

CF is a genetic disease that affects an estimated 70,000 to 100,000 patients worldwide and causes early morbidity and mortality. CF currently has no cure. The median age of death for CF patients is 27, and more than 90% of CF patients die from respiratory failure. To date, all but one of the therapies approved to treat CF patients are designed to treat the symptoms of CF rather than address the underlying cause. CF is caused by mutations in the gene that encodes for a protein called cystic fibrosis transmembrane conductance regulator, or CFTR. Although there are more than 1,900 different genetic mutations that cause CF, the DF508 mutation that we are targeting is the most prevalent and is present in approximately 70% of all CF patients. In CF patients, this mutated gene and the resulting defective protein lead to the dysfunction of multiple organ systems, including the lungs, pancreas and gastrointestinal tract. In the lung airways, absence of functional CFTR protein leads to unusually thick, sticky mucus that clogs the lungs and increases vulnerability to chronic, life-threatening lung infections.

About QR-010

QR-010 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by repairing the mRNA defect encoded by the DF508 mutation in the CFTR gene of CF patients. The DF508 mutation is a deletion of three of the coding base pairs, or nucleotides, in the CFTR gene, which results in the production of a misfolded CFTR protein that does not function normally. QR-010 is designed to bind to the defective CFTR mRNA and guide the insertion of the three missing nucleotides, thus repairing the mRNA and subsequently producing wild-type, or normal CFTR protein. QR-010 is designed to be self-administered through a small, handheld aerosol delivery device, or nebulizer, in the form of a mist inhaled into the lungs. We believe this method could allow maximum exposure of QR-010 to the primary target organ, the lung, as well as significant exposure to other affected organs through systemic absorption into the blood. QR-010 has been granted orphan drug designation in the United States and the European Union.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494

Friday, June 26th, 2015 Uncategorized Comments Off on (PRQR) Enrollment Started in Global Phase 1b Cystic Fibrosis Study of QR-010

(EFOI) Becomes Exclusive Tubular LED Partner of the Green Apple Initiative

SOLON, Ohio, June 26, 2015  — Energy Focus, Inc. (Nasdaq:EFOI), a leader in LED lighting technologies, today announced it has formed a partnership with the Center for Green Schools (Center) at the U.S. Green Building Council (USGBC) to advance the mission of providing green schools for all students within this generation. As the exclusive partner in the tubular LED (TLED) category of USGBC’s Green Apple initiative, Energy Focus will support the Center’s work to create healthy, safe, and efficient learning environments.

Green Apple is a movement to put all children in schools where they have clean and healthy air to breathe, where energy and resources are conserved and where children can be inspired to dream of a brighter future. Through the Green Apple partnership, Energy Focus will help educate about the importance of LED lighting in sustainable buildings, environmental stewardship, and human health enhancement.

As a Green Apple partner, Energy Focus will donate a portion of the proceeds from the sale of each of its commercial TLED lamps, which will carry the USGBC and Green Apple marks, to the Center for Green Schools’ programs. Energy Focus’ TLED lamps offer schools a much lower carbon footprint and scotopically enhanced lighting while removing hazardous materials such as mercury when compared with fluorescent lights.

“We are extremely excited to have been selected as the exclusive tubular LED partner for Green Apple at USGBC,” said Eric Hilliard, President and Chief Operating Officer of Energy Focus, Inc. “This partnership allows us to offer the K-12 schools in the United States an educational platform to learn about tubular LED lighting technology and solutions for their educational and operational needs. The science behind our products indicates that beyond just the economic benefits LEDs offer, our lighting provides important ‘green’ benefits to the long-term welfare of our planet and better overall health to each student in our country’s schools.”

“Energy Focus is honored and pleased to join forces with the USGBC and its Center for Green Schools to expedite the LED adoption in the nation’s schools,” said James Tu, Executive Chairman and Chief Executive Officer of Energy Focus. “Numerous studies have shown that blue light, which fluorescent lights emit copiously, causes retinal degeneration, and children are particularly susceptible to such damage due to incomplete growth of yellow cells that protect the retinas. The results are less than optimal student health and learning. In contrast, Energy Focus LED tubes produce a much smoother, more natural spectrum and flicker-free light. Therefore, our LED lighting not only reduces lighting energy consumption, but could also improve student wellbeing in schools. Together with USGBC, we can now enlighten the schools’ environment for better sustainability, better health and better learning in the most timely fashion.”

Rachel Gutter, USGBC’s Senior Vice President of Knowledge and the Director of the Center for Green Schools remarks, “We are proud to welcome Energy Focus as our latest Green Apple partner. Like the Center for Green Schools, Energy Focus understands that where our children learn matters. We very much look forward to working together to transform our schools into healthy, efficient, and productive learning environments.”


The U.S. Green Building Council (USGBC) is transforming the way we design, build, maintain and operate our buildings, homes and communities. Better buildings are our legacy. USGBC is committed to a prosperous and sustainable future through cost-efficient and energy-saving green buildings, and works toward its mission of market transformation through its LEED green building program, robust educational offerings, a nationwide network of chapters and affiliates, the annual Greenbuild International Conference & Expo, and advocacy in support of public policy that encourages and enables green buildings and communities.

About Energy Focus

Energy Focus, Inc. is a leading provider of energy efficient LED lighting products and a developer of energy efficient lighting technology. Our LED Lighting products provide energy savings, aesthetics, safety and maintenance cost benefits over conventional lighting. Our long-standing relationship with the U.S. Government continues to enable us to provide energy efficient LED lighting products to the U.S. Navy and the Military Sealift Command fleets. Customers include national, state and local U.S. government agencies as well as Fortune 500 companies and many other commercial and industrial clients. Company headquarters are located in Solon, Ohio with additional sales offices in Washington, D.C., New York and the United Kingdom. For more information, see our web site at

CONTACT: Energy Focus, Inc.
         Investor Relations


         Darrow Associates, Inc.
         Peter Seltzberg
Friday, June 26th, 2015 Uncategorized Comments Off on (EFOI) Becomes Exclusive Tubular LED Partner of the Green Apple Initiative

(IDI) Appoints Michael Brauser as Executive Chairman of the Board

Leading Team of Renowned Technology-Industry Executives Positions IDI to Become a Leading Player in the High-Growth Data Fusion Industry

IDI, Inc. (NYSE MKT: IDI), an information solutions provider, today announced that Michael Brauser has been appointed Executive Chairman of the Board of Directors. Mr. Brauser replaces Robert Fried who remains a director on the Board.

Mr. Derek Dubner, Co-CEO of IDI, Inc. stated, “Since the completion of the strategic acquisition of Interactive Data by The Best One, Inc. (“TBO”), which Michael Brauser co-founded, and subsequent merger with IDI, we have realigned our infrastructure and put in place a team of leaders that bring together the unparalleled experience and expertise to transform the existing data fusion industry utilizing our advanced technology platform. We are honored to have Michael Brauser serve as Executive Chairman of our Board and to help lead our team.”

Michael Brauser has been a key player in the Data Fusion sector since its earliest days, having built market-leading companies that collectively have produced revenues of over $2 billion. These include, Kertz Security, which was acquired by Wayne Huizenga in 1995 for $28 million; Naviant, an internet marketing company that was sold to Equifax in 2001 for $135 million; Seisint, which Reed Elsevier purchased in 2004 for $775 million; 5to1, an Internet advertising company that Mr. Brauser sold to Yahoo in 2011 for $28 million; and Interclick, which was also acquired by Yahoo in 2011, for $280 million.

Since TBO’s merger with IDI in March 2015, a significant amount of progress has been made laying the groundwork for IDI to transform itself into a leading player within the Data Fusion industry. Having identified a tremendous need for more advanced data solutions in today’s information-driven world, IDI is now expanding its focus to include the Risk Management and Marketing industries, as well as Data Analytics.

Mr. Dubner continued, “The leadership assembled at IDI is comprised of industry executives who bring forth combined experience of 50+ years. We are excited to bring our cutting-edge, advanced data mining solutions to data-driven markets that demand today’s most advanced data fusion systems.”

About IDI, Inc.

IDI, Inc. is an information solutions provider focused on the multi-billion dollar data-fusion market. IDI delivers otherwise unattainable insight into the ever-expanding universe of consumer- and business-centric data. Through proprietary linking technology, advanced systems architecture, and a massive data repository, IDI will address the rapidly growing need for actionable intelligence to support the entirety of the risk management industry, for purposes including due diligence, risk assessment, fraud detection and prevention, authentication and verification, and more. Additionally, IDI’s cross-functional core systems and processes are designed to deliver an unrivalled level of clarity into consumer data to support advanced marketing analytics.


Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward looking statements include statements about whether we have put in place a team of leaders that bring together the unparalleled experience and expertise to transform the existing data fusion industry utilizing our advanced technology platform. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in IDI’s Annual Report on 10-K, filed with the SEC on April 15, 2015, as well as the other factors described in the filings that IDI makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

IRTH Communications
Media and Investor Relations Contact:
Andrew Haag, 877-368-3566
Managing Partner

Friday, June 26th, 2015 Uncategorized Comments Off on (IDI) Appoints Michael Brauser as Executive Chairman of the Board

(NANO) to Participate in 7th Annual CEO Investor Summit 2015

Investor Event Held Concurrently With SEMICON West in San Francisco

MILPITAS, Calif., June 25, 2015  — Nanometrics Incorporated (Nasdaq:NANO), a leading provider of advanced process control systems, announced today that company management will participate in the 7th Annual CEO Investor Summit 2015, being held on Wednesday, July 15, 2015 in San Francisco, California.

About The 7th Annual CEO Summit

The CEO Summit is an accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2015 in San Francisco.  The event is hosted by executive management from participating companies and features a “round-robin” format consisting of small group meetings, each 30 minutes in duration.

The CEO Investor Summit is by invitation only and is open to accredited investors and publishing research analysts.  As space is limited, please RSVP early. Hosts reserve the right to limit attendance as necessary. Last day for registration is July 3, 2015.

While held concurrently with SEMICON West and Intersolar 2015, the event is not affiliated with the show.

RSVP Contacts for 7th Annual CEO Summit 2015

To RSVP for the CEO Summit, please contact either of the Summit’s co-chairs.

Laura J. Guerrant-Oiye Claire E. McAdams
Guerrant Associates Headgate Partners LLC
Phone: (808) 882-1467 Phone: (530) 265-9899
Email: Email:

About Nanometrics

Nanometrics is a leading provider of advanced, high-performance process control metrology and inspection systems used primarily in the fabrication of semiconductors and other solid-state devices, such as data storage components and discretes including high-brightness LEDs and power management components.  Nanometrics’ automated and integrated metrology systems measure critical dimensions, device structures, overlay registration, topography and various thin film properties, including film thickness as well as optical, electrical and material properties. The company’s process control solutions are deployed throughout the fabrication process, from front-end-of-line substrate manufacturing, to high-volume production of semiconductors and other devices, to advanced wafer-scale packaging applications. Nanometrics’ systems enable advanced process control for device manufacturers, providing improved device yield at reduced manufacturing cycle time, supporting the accelerated product life cycles in the semiconductor market. The company maintains its headquarters in Milpitas, California, with sales and service offices worldwide. Nanometrics is traded on NASDAQ Global Select Market under the symbol NANO. Nanometrics’ website is

Investor Relations Contact:
Claire McAdams 
Headgate Partners LLC

Company Contact:
Jeff Andreson
Thursday, June 25th, 2015 Uncategorized Comments Off on (NANO) to Participate in 7th Annual CEO Investor Summit 2015

(CYNA) APL-130277 Improved Parkinson’s Symptoms

Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson’s Disease

TORONTO, ONTARIO–(June 25, 2015) – Cynapsus Therapeutics Inc. (NASDAQ:CYNA)(TSX:CTH) (the “Company”) today announced that it presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of OFF episodes associated with Parkinson’s disease (PD). Data from the Company’s CTH-105, CTH-104 and CTH-103 clinical studies, presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) in San Diego, California, showed APL-130277 significantly improved PD symptoms (as measured by MDS-UPDRS Part III), rapidly turned patients from the OFF to ON state and was generally safe and well tolerated.

“Phase 1 and Phase 2 data presented at the Congress demonstrated that APL-130277 can achieve the appropriate apomorphine plasma levels needed to rapidly and reliably convert a patient from the OFF to the ON state. In addition, APL-130277 was safe and effective for the acute treatment of OFF episodes in PD patients,” said Jordan Dubow, M.D., Vice President, Medical Affairs, Cynapsus Therapeutics. “These data lead in to our Phase 3 pivotal studies to assess the efficacy, safety and tolerability of APL-130277 for the acute, on-demand management of OFF episodes.”

Presentations at MDS included:

  • Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson’s disease; Hauser et al.
    • CTH-105 was a Phase 2 open-label multicenter study in which APL-130277 was assessed in 19 patients with PD who experienced OFF episodes, with a total duration of at least two hours of OFF episodes daily.
    • Of the 19 total patients dosed, 15 achieved a full ON response. Of the four non-responders, two were dosed incorrectly and two were dosed up to the maximum available dose (30mg).
    • Sublingually administered APL-130277 rapidly converted PD patients from the morning OFF state to the full ON state with 100% of responders turning fully ON within 30 minutes and 40% within 15 minutes.
    • APL-130277 provided, rapid, clinically meaningful and statistically significant improvement in motor function as assessed by MDS-UPDRS Part III score at all time points assessed (i.e. 15, 30, 45, 60 and 90 minutes) with a mean maximal improvement of 18.9 points in the intent to treat population.
    • Thirteen of the 15 patients that turned ON remained ON for at least 30 minutes, nine of whom remained ON for at least 60 minutes, with a mean duration of ON of over 50 minutes.
    • The percentage change in MDS-UPDRS Part III was approximately 30% or greater at all time points measured, with a maximum mean percentage change at any time point of 45.6% for the intent to treat population. Mean percentage change of approximately 30% is generally considered a clinically meaningful level at which point patients turn ON.
  • Safety of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson’s disease; Isaacson et al.
    • In the CTH-105 study, a total of 77 doses of APL-130277 were administered to the 19 patients who completed dosing.
    • APL-130277 was safe and well-tolerated by all of the PD patients in the study.
    • Rates of adverse events (AEs) were similar to other dopamine agonists.
    • There were no related serious AEs, no AEs of local oral mucosal irritation, and no subjects discontinued due to an AE or any other reason.
  • Pharmacokinetics, Safety and Tolerability of High-dose Sub-lingually Administered APL-130277 in Healthy Volunteers; Agro et al.
    • CTH-104 was a single-center, Phase 1 study that evaluated the pharmacokinetic (PK) profile, safety and tolerability of a single dose of APL-130277 25mg in healthy volunteers. Eleven subjects were dosed with APL-130277 25mg and two with placebo.
    • In healthy volunteers, the higher dose of APL-130277 (25mg) administered sublingually demonstrated a favorable PK profile to support a rapid and sustained effect for acute relief of OFF episodes in PD patients.
    • Time to reach the known minimum efficacious plasma apomorphine concentration was achieved in under 10 minutes and apomorphine levels were maintained above this concentration for over 2.5 hours.
    • PK results demonstrated dose proportionality to lower doses and the PK curve remained rounded.
    • The AEs reported were mild to moderate in severity with no serious AEs.
  • Pharmacokinetics, Safety and Tolerability of Sublingually Administered APL-130277 Compared to Subcutaneous Apomorphine in Healthy Volunteers; Agro et al.
    • CTH-103 was a single-center, Phase 1 crossover study that evaluated the PK profile, safety and tolerability of two doses of APL-130277 (10mg and 15mg) compared to subcutaneous apomorphine in healthy volunteers (2mg and 3mg).
    • Sublingually administered APL-130277 reached known therapeutic apomorphine plasma levels comparable to subcutaneous apomorphine with a longer duration over the minimum efficacious plasma concentration.
    • APL-130277 demonstrated a more rounded peak, lower maximal concentration and less steep rise to maximal concentration compared to subcutaneous apomorphine, leading to less dopaminergic AEs. This was evident as a higher incidence of nausea and vomiting was reported when subjects were given the subcutaneous apomorphine versus APL-130277.
    • APL-130277 was demonstrated to be safe and well-tolerated and no subjects discontinued treatment with APL-130277 due to an AE.

About Cynapsus

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a Phase 3, fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson’s disease (PD).

Forward-Looking Statements

This announcement contains “forward-looking statements” within the meaning of applicable securities laws. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe”, “may”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “expect”, “predict”, “potential”, or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, in include, but are not limited to those factors identified under the caption “Risk Factors” in the Company’s filings and reports in the United States with the United States Securities and Exchange Commission (the “SEC”) available on the SEC’s web site, and in Canada with the various Canadian securities regulators, which are available online at Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.

Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225

Cynapsus Therapeutics
Andrew Williams
(416) 703-2449 x253

Russo Partners LLC
Matt Middleman
(212) 845-4272

Thursday, June 25th, 2015 Uncategorized Comments Off on (CYNA) APL-130277 Improved Parkinson’s Symptoms

(IACI) Announces Intent to Pursue IPO of The Match Group

— Appoints Joey Levin CEO of IAC

NEW YORK, June 25, 2015  — IAC/InterActiveCorp (NASDAQ: IACI) announced today that its Board of Directors has approved the pursuit of an initial public offering (IPO) of newly-issued shares of common stock of The Match Group.  IAC also announced that Joey Levin, formerly CEO of its Search & Applications business, has been named CEO of IAC and joined its Board of Directors.  Greg Blatt will remain Chairman, and Sam Yagan CEO, of The Match Group.

“As many know from our actions over the last 20 years, I’m not a believer in simply agglomerating assets in perpetuity.  I’ve long felt that as entities grow into size and maturity it’s healthy to give them separation and independence from a mother church,” said Barry Diller, IAC’s Chairman and Senior Executive.  “Over the last two decades, IAC and its progeny have grown into seven separate public companies with a current shareholder value of over $44 billion – given that we started with a base of $275 million, it’s a more than satisfactory record.  As part of this evolution, in 2008 we spun off four companies simultaneously, leaving us with a much smaller IAC.  Since that time we’ve grown the Company substantially, more than quadrupling the Company’s value, with The Match Group leading the way – and so now, under the superb leadership of Greg Blatt and Sam Yagan, we want to take the step of offering the public the ability to own shares directly in this singular area of Internet activity.”

“As for IAC, we now have a group of assets with great potential and, with the appointment of Joey Levin as CEO, a leader who has the youth, energy and ability to develop them in hopefully the same growth track as has been demonstrated throughout our twenty year history.  We start with nearly 20 individual businesses, a strong balance sheet and I believe the same level of ambition as we had at the beginning.  I’m really confident that Joey and his nearly 4,000 employees have the resources and talent to build another great pile of assets, and to perpetually spin them out to the benefit of shareholders: it’s a unique model, worth both preserving and reinvigorating.”

“Today’s changes highlight both the incredible historical success at The Match Group and the exciting collection of assets within IAC,” said Mr. Levin.  “At IAC, we have companies with extraordinary potential in very large markets, a strong balance sheet, and an excellent team.  In my 12 years at IAC, the one constant has been our ability to find, nurture, and grow businesses to global scale by giving great people great opportunities and access to the resources to be ambitious.  Our current portfolio of businesses, combined with judicious use of our balance sheet, provides a tremendous opportunity to deliver value in the years ahead.”

IAC expects The Match Group to issue less than 20% of its common stock in the initial public offering, with IAC’s remaining stake in The Match Group represented by both high- and low-vote common shares. The IPO is expected to be completed during the fourth quarter of this year.

“The Match Group is poised for substantial growth in the coming years,” said Mr. Blatt.  “The dating industry has come a long way since its inception, but the category remains underpenetrated.  We believe the combination of our more established businesses such as Match, Meetic, and OurTime, and earlier stage businesses such as Tinder and OkCupid, creates an attractive combination of significant cash flow generation, strong margins and meaningful growth potential.  We believe the natural expansion of the market and our portfolio approach to capturing it provide a strong foundation for our future success.  Sam and I look forward to continuing to lead this company and its incredibly talented and dedicated teams of employees into this exciting next chapter.”

IAC also announced today that Chief Financial Officer Jeff Kip is resigning from the company to spend more time with his family in Boston, and to pursue other interests. Mr. Kip will remain with IAC for an interim period and will help with transition to a new CFO.

“Jeff has been a strong and talented executive over the last three years,” said Diller.  “We thank him for his many contributions, fully support his decision to move closer to his family and thank him for his help in transitioning to his successor.”

Mr. Kip has served as Executive Vice President and Chief Financial Officer since March 2012, and has been responsible for overseeing corporate finance, investor relations, accounting, tax, treasury and M&A at IAC.

“I am grateful to Barry and the IAC management team for affording me the opportunity to serve as the CFO of such a great, dynamic company,” said Kip.  “Today’s announcements make clear that exciting times lie ahead for IAC, and I am confident that Joey Levin’s leadership of the enterprise will take it to new heights and in exciting directions.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About IAC

IAC (NASDAQ: IACI) is a leading media and Internet company. It is organized into four segments: The Match Group, which consists of dating, education and fitness businesses with brands such as, OkCupid, Tinder, The Princeton Review and DailyBurn; Search & Applications, which includes brands such as,, and Investopedia; Media, which consists of businesses such as Vimeo, Electus, The Daily Beast and CollegeHumor; and eCommerce, which includes HomeAdvisor and ShoeBuy.  IAC’s brands and products are among the most recognized in the world reaching users in over 200 countries.  The Company is headquartered in New York City and has offices worldwide. To view a full list of IAC companies, please visit

About Joey Levin

Joey Levin has served as the CEO of IAC Search & Applications, overseeing the desktop software, mobile applications, and media properties that comprises IAC’s Search & Applications segment, including, Apalon,,,  Citysearch, CityGrid,, Investopedia, Mindspark, PriceRunner, and SlimWare.  Prior to being appointed to his role at IAC Search & Applications, Mr. Levin served as Senior Vice President, Mergers & Acquisitions and Finance for IAC, and held various roles within IAC since joining the company in 2003. Prior to joining IAC, Mr. Levin worked in the Technology Mergers & Acquisitions group for Credit Suisse First Boston (now Credit Suisse) in San Francisco advising public and private technology and e-commerce companies on a variety of transactions.  Mr. Levin graduated from the Jerome Fisher Program in Management & Technology from the University of Pennsylvania, with a B.S. in Economics from the Wharton School and a B.A.S. in Engineering from the School of Engineering and Applied Sciences.

About The Match Group

The Match Group is the world’s leading provider of dating products, redefining the way millions of people meet, date and start relationships every day. We offer our products under nearly 50 brands, translated into nearly 40 languages and available in more than 200 countries across five continents.  Our principal brands include Match, Tinder, Meetic, OkCupid and OurTime.  We generate revenues through a combination of subscription, transaction and advertising models, distributed through desktop and mobile devices. Each product within our portfolio caters to different communities defined by geography, demographics and relationship sensibility. More than 7 million people sign up for our products every month.  The Match Group also operates The Princeton Review and DailyBurn, two businesses outside the dating space that leverage the company’s experiences in direct-to-consumer digital service business models.  For more information please visit

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains “forward‑looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  The use of words such as “anticipates,” “expects,” “intends,” “plans” and “believes,” among others, generally identify forward-looking statements.  These forward-looking statements include statements relating to: future financial performance, business prospects and strategy, anticipated trends, prospects in the industries in which our businesses operate and other similar matters.  These forward‑looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict.  Actual results could differ materially from those contained in these forward‑looking statements for a variety of reasons, including, among others: changes in senior management at IAC or its businesses, changes in our relationship with Google, adverse changes in economic conditions, adverse trends in the online advertising industry, our ability to convert visitors to our websites into users,  risks relating to acquisitions, technology changes, our ability to expand successfully into international markets and regulatory changes. Certain of these and other risks and uncertainties are discussed in IAC’s filings with the Securities and Exchange Commission (“SEC”).  Other unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise from time to time.  In light of these risks and uncertainties, these forward‑looking statements may not prove to be accurate.  Accordingly, you should not place undue reliance on these forward‑looking statements, which only reflect the views of our management as of the date of this press release.  We do not undertake to update these forward-looking statements.

Contact Us

IAC Investor Relations
Mark Schneider / Alexandra Caffrey
(212) 314-7400

IAC Corporate Communications
Isabelle Weisman
(212) 314-7361

555 West 18th Street, New York, NY 10011 (212) 314-7300

Thursday, June 25th, 2015 Uncategorized Comments Off on (IACI) Announces Intent to Pursue IPO of The Match Group

(MZOR) Purchase Orders for Two Renaissance® Systems in U.S. & Spain

Expands European Presence with First Order in SpainRepresents 4th & 5th System Orders to Date in Second Quarter

Mazor Robotics Ltd. (TASE:MZOR) (NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, announced today that it received purchase orders for two Renaissance systems.

One system was purchased by NEUROINSTITUT OLIVER-AYATS Barcelona, Spain. It marks the first Renaissance system to be purchased in the country and will be installed at a leading neurosurgical center in Barcelona.

The other system was purchased by a hospital in Indiana (US), making this the first system to be purchased in that state.

“I am very pleased with the momentum we are experiencing both in the US and the international markets,” commented Ori Hadomi, Chief Executive Officer. “In Europe we continue to see opportunities and this is the first Renaissance system in Spain, while in the US, we are expanding Mazor’s presence into new markets.”

These Renaissance systems represent the fourth and fifth purchase orders received to date during the second quarter ending June 30, 2015. In accordance with Mazor Robotics’ disclosure policy, the Company will announce the total number of system orders following the end of the second quarter.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the Company’s momentum in the US and international markets, that the Company is seeing opportunities in Europe, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.


Mazor Robotics Inc.
189 S. Orange Ave., Suite 1850
Orlando, FL 32801
Tel: 1 (800) 80-MAZOR
Fax: (407) 591-3560
Mazor Robotics Ltd.
PO Box 3104, 7 HaEshel St.
Caesarea Park South
3088900 Israel
Tel: +972 4 618-7100
Fax: +972 4 618-7111
Mazor Robotics GmbH
Borkstraße 10
48163 Münster, Germany
Tel: +49 251 703 666 0
Fax: +49 251 703 666 52
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors;
212.850.6020; 415.652.9100
David Schemelia – Media

Thursday, June 25th, 2015 Uncategorized Comments Off on (MZOR) Purchase Orders for Two Renaissance® Systems in U.S. & Spain

(RGSE) Improves Capitalization Structure, Subordinated Debt, Warrant Overhang

LOUISVILLE, Colo., June 25, 2015  — RGS Energy (Nasdaq:RGSE), one of the nation’s leading rooftop installers of solar equipment, has converted all of its subordinated debt to Class A common stock and entered into agreements to exchange a substantial amount of its Series A and C warrants for Class A common stock.

The subordinated debt transaction involved converting outstanding principal of $3.15 million and accrued interest of $1.09 million under loans from Riverside Fund III, L.P., an affiliate of the company’s largest shareholder, Riverside Renewable Energy Investment, LLC into 1,288,156 shares of the company’s Class A common stock at $3.29 per share, the closing price on June 23, 2015.

“In addition to eliminating our subordinated debt and improving our working capital, the conversion of this debt held by Riverside, our largest shareholder and whose director is our chairman, demonstrates their confidence in our turn-around progress and plans,” said Dennis Lacey, president and CEO of RGS Energy.

The company also has entered into agreements to exchange Series A and Series C warrants for an aggregate of 1,330,000 shares of Class A common stock. The consummation of the exchange is subject to certain closing conditions, one of which is that the NASDAQ Stock Market has completed its review of the transaction without objection.

During the second quarter of 2015, Series B warrants were exercised into 1,564,787 shares of Class A common stock, providing net proceeds of more than $4 million. After consummation of the warrant exchange transaction described above, substantially all Series A, B, C, D and E common stock warrants will have been exercised or exchanged.

About RGS Energy

RGS Energy (Nasdaq:RGSE) is one of the nation’s leading rooftop installers of solar equipment, serving residential and small business customers in the mainland U.S. and Hawaii. Beginning with one of the very first photovoltaic panels sold in 1978, the company has installed tens of thousands solar power systems. RGS Energy makes it very convenient for customers to save on their energy bill by providing a comprehensive solar solution, from design, financing, permitting and installation to ongoing monitoring, maintenance and support.

For more information, visit, on Facebook at and on Twitter at RGS Energy is a trade name and RGS Energy makes filings with the Securities and Exchange Commission under its official name “Real Goods Solar, Inc.” For more information about the company, visit

Forward-Looking Statements and Cautionary Statements

This press release may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they provide our current beliefs, expectations, assumptions and forecasts about future events. The words “may,” “will” and similar expressions as they relate to us are intended to identify such forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking statements include, without limitation, the factors discussed throughout Part I, Item 1A, Risk Factors and Part II, Item 7, Management’s Discussion and Analysis of Financial Conditions and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2014.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. These documents are available on both the EDGAR section of the SEC’s website at and the Investor Relations section of the company’s website at

CONTACT: Media and Investor Relations Contact
         Ron Both
         Liolios Group, Inc.
         Tel 1-949-574-3860
Thursday, June 25th, 2015 Uncategorized Comments Off on (RGSE) Improves Capitalization Structure, Subordinated Debt, Warrant Overhang

(CBLI) Enters $25 Million Equity Financing Private Placement

BUFFALO, NY–(Jun 25, 2015) –  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into a securities purchase agreement with David Davidovich, a venture capital investor, for the sale of 6,459,948 unregistered common shares at a price of $3.87 per share for an aggregate of $25 million. The offering represents a 35% premium to the closing market price of $2.86 on June 23, 2015 and a 21% premium to the trailing 60-day volume weighted average price, as reported by Bloomberg. The parties expect to close the transaction on or about July 6, 2015.

The Company also announced that NASDAQ has granted the Company’s request for a financial viability exception to the shareholder approval requirements otherwise applicable to this transaction. The Audit Committee of the Company’s Board of Directors, which is comprised solely of independent, disinterested directors, approved the Company’s reliance on the NASDAQ financial viability exception. In accordance with NASDAQ requirements, the Company will mail a letter to stockholders notifying them of its intention to close the transaction without obtaining approval from its stockholders.

Yakov Kogan, PhD, MBA, Chief Executive Officer, commented, “We are pleased to partner with a long-term investor who shares our confidence in CBLI’s future prospects and recognizes the value of our team and pipeline. We believe this investment provides us with sufficient capital to pursue commercialization of entolimod’s biodefense indication, assuming a positive outcome to the ongoing review of our pre-Emergency Use Authorization dossier by the U.S. Food and Drug Administration, and advance development of our oncology and vaccine adjuvant programs.”

Mr. Davidovich stated, “I believe in the strong potential of CBLI’s products and its team and hope that my investment will provide the company with the necessary support to fully realize its goals.”

In connection with the private placement, the Company’s Board of Directors will increase from 6 to 13 members, 7 of which will be appointed by the new investor. The Company has also agreed to file a registration statement under the Securities Act of 1933, as amended (the “Act”) covering the resale of shares of Common Stock within 16 months after the closing of this transaction; however under the terms of the agreement, the shares will not be eligible for resale until the second anniversary date of closing. These securities have not been registered under the Act and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), acted as financial advisor to the Company.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company’s proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company’s most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and through two joint ventures, Panacela Labs, Inc. and Incuron LLC. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company’s website at

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as “plan,” “potential,” “will,” “look forward,” “believe” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the conduct and results of our various clinical trials; the efficacy of our therapeutic products; our ability to successfully complete planned clinical studies; and our ability to obtain regulatory approval for our therapeutic products. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These factors include, among others, the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s collaborative relationships and the financial risks related thereto; the Company’s ability to comply with its obligations under license agreements; the Company’s inability to obtain regulatory approval in a timely manner or at all; the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company’s need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company’s R&D grants and contracts and its ability to win additional funding under such grants and contracts. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.

Cleveland BioLabs, Inc.
Rachel Levine
Vice President, Investor Relations
T: 917-375-2935

Thursday, June 25th, 2015 Uncategorized Comments Off on (CBLI) Enters $25 Million Equity Financing Private Placement

(TGEN) Sells Combined Heat and Power System to New York Hospital

WALTHAM, Mass., June 24, 2015  — Tecogen® Inc. (NASDAQ: TGEN) today announced the sale of a CM-75 combined heat and power (CHP) module for installation at a hospital in Long Island, New York. The unit is being sold to a local Energy Services Company (ESCO) who will replace an existing outdated cogeneration system with Tecogen’s current technology.  The CHP system will provide electrical power for the hospital while supplying the hot water needed for operations.  The resulting cost reduction quickly recovers the system cost while continuing to reduce the hospital’s carbon footprint.

“Hospitals are ideal candidates for combined heat and power (CHP) systems,” said Robert Panora, President and COO of Tecogen.  “Hospitals function 24 hours a day, 365 days a year, and require round-the-clock reliable energy.  Combined systems enable hospitals to reduce energy costs, improve environmental performance, and increase energy reliability.  Resources saved are often redirected to improve patient care.”

The new CM-75 CHP unit will improve the environmental footprint of the hospital be incorporating advanced emissions technology developed by Tecogen.

About Tecogen

Tecogen manufactures, installs, and maintains high efficiency, ultra-clean combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a building’s carbon footprint.

In business for over 20 years, Tecogen has shipped more than 2,000 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit

Tecogen Media Contact Information:
David Garrison
P: 781-466-6403

Tecogen Investor Contact Information:
John N. Hatsopoulos
P: 781-622-1120

Wednesday, June 24th, 2015 Uncategorized Comments Off on (TGEN) Sells Combined Heat and Power System to New York Hospital

(QBAK) Announces the Q1™, an LTFS Single Drive Archive Appliance

Qualstar Corporation (NASDAQ: QBAK), a manufacturer of data and archive storage solutions as well as high efficiency power supplies, announces the release of Q1, a standalone LTFS archive solution for transfer and archive of data.

The Qualstar Q1 is an innovative, unique self-contained and cost effective solution for professionals who want to archive, review or restore using the LTFS file format. Feature-rich and compact, the Q1 can automatically transfer your digital data in the field to LTFS formatted LTO6 tapes for interchange with your main digital repository. This easily carried system is designed to be used on location to offload data from various sources or connected devices for consolidation and backup. Qualstar provides leading-edge technology based on industry standards that effectively offer outstanding performance at the right value point.

“We are pleased to add the Q1 to our portfolio of products, and continue to deliver world-class technology and expertise in an easy to install, turn-key appliance. Our recent product announcements demonstrate Qualstar’s dedication to revitalizing and solidifying its future,” said Steven N. Bronson, Qualstar’s Chief Executive Officer.

“The Q1 addition brings great value, as it can be used to help save time by streamlining file-based workflows in both the field and in the post production environment. Our customers will appreciate the benefits of an all-in-one, ready-to-go, high performance solution that you can take with you,” added Daniel K. Jan, Qualstar’s President.

About Qualstar Corporation

Qualstar, founded in 1984, is a diversified electronics manufacturer specializing in data storage and power supplies. Qualstar’s products are known throughout the world for high quality and Simply Reliable™ designs that provide years of trouble-free service. More information is available at or by phone at 805-583-7744.

Connect with Qualstar on LinkedIn or Twitter.

FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements relating to expectations, plans or prospects for Qualstar Corporation that are based upon the current expectations and beliefs of Qualstar’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Notwithstanding changes that may occur with respect to matters relating to any forward looking statements, Qualstar does not expect to, and disclaims any obligation to, publicly update any forward-looking statements whether as a result of new information, future events or otherwise. Qualstar, however, reserves the right to update such statements or any portion thereof at any time for any reason. In particular, the following factors, among others, could cause actual or future results to differ materially from those suggested by the forward-looking statements: Qualstar’s ability to successfully execute on its strategic plan and meet its long-term financial goals; Qualstar’s ability to successfully implement and recognize cost savings; Qualstar’s ability to develop and commercialize new products; industry and customer adoption and acceptance of Qualstar’s new products; Qualstar’s ability to increase sales of its products; the rescheduling or cancellation of customer orders; unexpected shortages of critical components; unexpected product design or quality problems; adverse changes in market demand for Qualstar’s products; increased global competition and pricing pressure on Qualstar’s products; and the risks related to actions of activist shareholders, including the amount of related costs. For further information on these and other and other cautionary statements, please refer to the risk factors discussed in Qualstar’s filings with the U.S. Securities and Exchange Commission including, but not limited to, Qualstar’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of such Form 10-K, and any subsequently filed reports. All documents also are available without charge through the SEC’s website ( or from Qualstar’s website (

Qualstar Corporation
Heather Mayer, 805-416-7001

Wednesday, June 24th, 2015 Uncategorized Comments Off on (QBAK) Announces the Q1™, an LTFS Single Drive Archive Appliance

(TIL) Names Sard Verbinnen as Investor Relations Firm

HAMILTON, Bermuda, June 24, 2015  — Till Capital Ltd. (Nasdaq:TIL) (TSX-V:TIL) (the “Company” or “Till“), a Bermuda domiciled company, is pleased to announce it has retained the services of Sard Verbinnen & Co. as the Company’s Investor Relations firm.

Sard Verbinnen & Co.

Sard Verbinnen & Co. provides strategic communications advice and services to multinational corporations, smaller public and private companies, investment firms, professional services firms, educational and cultural institutions, and high-profile individuals. The firm, which was founded in 1992, employs 130 people in New York, Chicago, San Francisco, Los Angeles, and London.

“It was our goal, once trading on the NASDAQ, to identify and select a prestigious U.S. based investor relations firm with a depth of expertise in the insurance industry. We selected Sard Verbinnen & Co because of its expertise in shareholder communications and the relationships they have developed within the investment community,” said William M. Sheriff, Chairman & Chief Executive Officer, Till Capital Ltd. “We look forward to working with their team to establish an effective communications channel.”

In consideration of the investor relations services to be provided by Sard Verbinnen, the Company has agreed to a standard time and cash fee structure starting on June 16th, 2015. Sard Verbinnen does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest in connection with the provision of the services or otherwise. The services may be terminated by the Company on 30 days’ notice.

Till Capital Ltd. has terminated its contract with Renmark Financial Communications Inc. (“Renmark”) and thanks Renmark for services provided.

Till Capital Ltd.

Till Capital Ltd. is a Bermuda-domiciled company with two wholly-owned subsidiaries, Omega Insurance Holdings Inc. and Resource Re Ltd. Omega Insurance Holdings Inc. owns Omega General Insurance Company, a Canadian insurance company offering innovative and customized insurance industry solutions, including fronting and run-off services for insurers/reinsurers, within the Canadian marketplace. Omega Insurance Holdings Inc. also operates Focus Group Inc., a consulting and project management company servicing the local and international needs of its Property Casualty Insurance clients. Resource Re Ltd. is a Bermuda-domiciled reinsurance company regulated by the Bermuda Monetary Authority with a Class 3A insurance license directed to underwrite reinsurance policies within a long term investment strategy. Through its regulated subsidiaries, the Company has been structured to produce underwriting profits as well as above average returns on assets under management.

Cautionary Note

At this time, the Company has no current plans to provide earnings guidance due to the volatility of investment returns.

The Till Capital shares are restricted voting shares, whereby no single shareholder of Till Capital is able to exercise voting rights for more than 9.9% of the voting rights of the total issued and outstanding Till Capital shares (the “9.9% Restriction“). However, if any one shareholder of Till Capital beneficially owns, or exercises control or direction over, more than 50% of the issued and outstanding Till Capital shares, the 9.9% Restriction will cease to apply to the Till Capital shares.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Till Capital or any other securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. Trading in the securities of Till Capital should be considered speculative.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Bermuda Monetary Authority accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward Looking Information

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities laws. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995, and generally can be identified by phrases such as “plan,” “except,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “will,” “could” and other similar words, or statements that certain events or conditions “may” occur. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, Till Capital assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.

CONTACT: Till Capital Ltd.
         William M. Sheriff
         Chairman and Chief Executive Officer
         (208) 635-5415
Wednesday, June 24th, 2015 Uncategorized Comments Off on (TIL) Names Sard Verbinnen as Investor Relations Firm

(EVOK) Publication of Clinical Data On EVK-001 In Diabetic Gastroparesis

Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray

SOLANA BEACH, Calif., June 24, 2015  — Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that previously disclosed results from its Phase 2b clinical trial evaluating EVK-001, its patented intranasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women, have been published in the July issue of Clinical Gastroenterology and Hepatology, a leading peer‑reviewed journal published by the American Gastroenterological Association (AGA).

Henry P. Parkman, M.D., Director of the GI Motility Laboratory at the Temple University School of Medicine, commented, “These Phase 2 data demonstrate EVK-001’s potential as an effective treatment that is well-tolerated by women suffering from diabetic gastroparesis. Approximately 80% of all diagnosed diabetic gastroparesis patients are women. This is not surprising given that women have shown to have slower gastric emptying when compared to men, a difference in genders that has been well established in the medical community.

“Overall, data from controlled clinical trials continue to show that Evoke’s novel intranasal spray is an optimal route of administration for these patients who have few treatment options. Unlike oral formulations that can have erratic absorption from the GI tract, EVK-001’s absorption is not impaired by delayed gastric emptying and symptoms, such as vomiting. This is especially important during gastroparesis symptom flares.”

The US multicenter, double-blind, randomized Phase 2b study enrolled and dosed 285 patients (71% female) with type 1 or type 2 diabetes and a previous diagnosis of gastroparesis. The pre‑specified efficacy endpoints evaluated the response to treatment in male subjects and female subjects separately. In female subjects, gastroparesis symptom scores showed a statistically and clinically significant improvement when given EVK-001 compared with placebo. In male subjects, EVK-001 was not shown to improve symptom scores when compared to placebo. There were no drug-related serious adverse effects reported during the study and the most common adverse events were altered taste, headache, and fatigue.

Marilyn Carlson, D.M.D., M.D., RAC, Evoke’s Chief Medical Officer, said, “Collectively, our two Phase 2 diabetic gastroparesis studies confirm the effectiveness, absorption, and tolerability of Evoke’s patented formulation of metoclopramide when delivered as a nasal spray. Importantly, results from our Phase 2b study further establish that EVK-001 provides clinically meaningful benefits for female patients, rather than male, and that patient gender is predictive of EVK-001’s benefits. These data subsequently served as the basis for our agreement with the FDA to focus our currently ongoing Phase 3 trial on women with symptomatic diabetic gastroparesis.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Visit for more information.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding the enrollment completion of Evoke’s ongoing Phase 3 clinical trial of EVK-001, the potential approval and commercialization of EVK-001 as a new and effective treatment for gastroparesis and Evoke’s completed and ongoing trials and studies serving as a basis for submission of an NDA and the sufficiency of Evoke’s resources to fund operations through 2015. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in Evoke’s business, including, without limitation: Evoke is entirely dependent on the success of EVK-001, for which it has commenced a Phase 3 clinical trial and male companion trial, and Evoke cannot be certain that it will be able to obtain regulatory approval for, or successfully commercialize, EVK-001; the results observed in female patients with symptoms associated with acute and recurrent diabetic gastroparesis in Evoke’s Phase 2b clinical trial of EVK-001 may not be predictive of the safety and efficacy results in the Phase 3 clinical trial; the inherent risks of clinical development of EVK-001, including continued delays in enrollment and completion of the Phase 3 trial as well as potential delays in any other clinical trials and studies; Evoke may spend its available cash faster than it anticipates; Evoke will require substantial additional funding to complete the Phase 3 clinical trial and potentially commercialize EVK-001 as well as to finance additional development requirements, and may be unable to raise capital when needed, including to fund ongoing operations; the potential for adverse safety findings relating to EVK-001 to delay or prevent regulatory approval or commercialization; Evoke’s reliance on outsourcing arrangements for many of its activities, including clinical development and supply of EVK-001; and other risks detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CONTACT: Investor / Media Contact:
         The Ruth Group
         David Burke / Kirsten Thomas
         Tel: 646-536-7009 / 7014 /
Wednesday, June 24th, 2015 Uncategorized Comments Off on (EVOK) Publication of Clinical Data On EVK-001 In Diabetic Gastroparesis

(CPXX) Positive Results from Phase 3 AML Study of CPX-351

CPX-351 demonstrates a 43.2% relative improvement in induction response rate Conference call today at 8:30am Eastern Time to discuss the results

EWING, N.J., June 24, 2015  — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML).  The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen).

Data on overall survival, the primary endpoint, are expected in the first quarter of 2016. However, induction response rate is a key secondary endpoint in the study and has been an important surrogate of overall survival and clinical benefit in this patient population.  These data validate the induction response rates observed in the Phase 2 study, which was associated with a marked improvement in overall survival.

“The results are encouraging because this is the third randomized study in which CPX-351 outperformed the control arm of cytarabine plus an anthracycline in overall response rate,” said Jeffrey Lancet, M.D., Senior Member and Chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center and lead investigator on the Phase 3 study.  “With induction therapy for AML, response rate has historically served as a surrogate for overall survival, and these data suggest a clinically meaningful benefit for CPX-351 over standard chemotherapy.”

Gail Roboz, M.D., Associate Professor of Medicine and Director of the Leukemia Program at the Weill Medical College of Cornell University and the NewYork-Presbyterian Hospital in New York added, “The magnitude of the CR+CRi rate increase is promising and we may be one step closer to having a superior treatment option for patients with this devastating disease. The improvement in response rate portends well for a clinically meaningful survival benefit.”

The randomized, controlled, Phase 3 study evaluated 309 patients, aged 60-75 years, from 39 clinical centers in the U.S. and Canada, with untreated high-risk (secondary) AML.  Patients were randomized 1:1 to receive either CPX-351 or the 7+3 regimen. In addition to induction response and overall survival, other important information, such as rate of morphologic leukemia-free state, best overall response, response duration, event-free survival, and early mortality, as well as pharmacoeconomic comparisons, will be assessed and available at the conclusion of the study.  The Leukemia & Lymphoma Society® has partnered with Celator in the development of CPX-351.

“We are very pleased with the induction response rate results. This is one of the largest trials conducted in this specific patient population, and based on the improvement seen with CPX-351, we are optimistic about the opportunity for CPX-351 to improve overall survival in this patient population,” said Scott Jackson, Celator’s Chief Executive Officer. “We look forward to the continued follow up of these patients.  If approved, CPX-351 will be well-positioned to become the standard of care for high-risk AML patients.  Further, we believe that significant opportunities exist for the additional development of CPX-351 as the backbone of treatment for AML and other blood cancers.”

Data on the primary endpoint of the study, overall survival, are expected in the first quarter of 2016.

Additional information regarding the study is available at

Conference Call Information:

Celator will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss the induction response results from its Phase 3 study. To participate in the conference call, please dial 877-303-6316 (domestic) or 650-521-5176 (international) and refer to conference ID 73362390. The live webcast of the call can be accessed in the Investors section of Celator’s website at An archived webcast will be available on Celator’s website beginning approximately two hours after the event.

About CPX-351

CPX-351 (cytarabine:daunorubicin) Liposome for Injection represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the U.S. Food & Drug Administration and the European Commission for the treatment of Acute Myeloid Leukemia (AML). Celator has conducted two randomized, controlled, Phase 2 studies with CPX-351. The first study was conducted in newly diagnosed elderly AML patients and the second study was conducted in patients with AML in first relapse. In both Phase 2 studies, treatment with CPX-351 resulted in significant improvements in response rates, 60-day mortality, and overall survival in the highest risk patients. The Leukemia & Lymphoma Society® has partnered with Celator in the development of CPX-351 starting in Phase 2 and continuing in Phase 3.

About AML

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates that there will be 20,830 new cases of AML and 10,460 deaths from AML in the U.S. in 2015. Additionally, it is estimated that the prevalence of AML across major global markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) is over 75,000. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.  CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor.  Celator’s pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. The company is advancing the CombiPlex platform and broadening its application to include molecularly targeted therapies and epigenetic modulators.

For more information, please visit Celator’s website at Information on ongoing trials is available at

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the potential safety, tolerability, efficacy and therapeutic and commercial potential of CPX-351, our expectations regarding our development plans for CPX-351 and our other drug candidates, the availability of data from clinical studies, and whether final results of clinical studies will be supportive of regulatory approvals required to market licensed products. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of clinical studies, availability of data from ongoing clinical studies, whether clinical study results for CPX-351 obtained to date will be predictive of future results, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator’s Form 10-K for the year ended December 31, 2014 and other filings by the company with the U.S. Securities and Exchange Commission.

Wednesday, June 24th, 2015 Uncategorized Comments Off on (CPXX) Positive Results from Phase 3 AML Study of CPX-351

(HEAR) Partners With AuDConnex For Directed Audio Hearing Solution

SAN DIEGO, June 24, 2015  — Turtle Beach Corporation (NASDAQ: HEAR), the leading-edge audio technology company, today announced a new partnership with AuDConnex, a major hearing healthcare buying group, further strengthening the Company’s channel and distribution strategy for HyperSound ClearTM. Planned to launch later this year, HyperSound Clear is Turtle Beach’s first-of-its-kind hearing healthcare solution for individuals with hearing loss. AuDConnex supports its wide network of members through technology innovations, ongoing training and education and competitive product pricing, and as part this newly formed partnership, AuDConnex members across the United States and Canada will have the opportunity to offer HyperSound Clear to patients once it becomes available.

Leveraging Turtle Beach’s patented directional audio technology, HyperSound Clear offers a fundamentally new approach to sound delivery. Similar to the way a flashlight beams a ray of light, HyperSound Clear beams sound directly to targeted listeners, which has been shown to improve sound clarity and speech intelligibility in individuals with hearing loss. When sitting in the “HyperSound® beam,” people with hearing loss experience immersive, 3D audio; and at the same time, everyone else in the room hears audio at a normal volume level delivered through the TV speakers or home theater system. This means that people with hearing loss, along with family members and friends, can once again return to the family room to enjoy the latest home entertainment together, whether watching their favorite movies and TV shows, enjoying the latest music or playing video games.

“This partnership with AuDConnex is a tremendous step toward bringing hearing loss awareness to a broader market,” said Rodney Schutt, Senior Vice President and General Manager for the HyperSound business at Turtle Beach Corporation. “HyperSound Clear provides AuDConnex members with a truly unique gateway solution that has the potential to lower the current five to seven year gap between a patient’s first visit with a hearing healthcare professional to hearing aid adoption. Together with AuDConnex we can strengthen member portfolios and elevate the level of hearing care available to providers.”

“The AuDConnex team sees great potential in HyperSound Clear as an entirely new ‘Directed Audio’ product category that will help patients hear better in one of the most difficult listening situations: watching TV,” said Michael Iliff, Doctor of Audiology and AuDConnex co-founder. “Nearly 85% of patients who visit a hearing specialist for the first time do so because they’re no longer able to hear and understand the TV as well as they used to. Adding a gateway product like HyperSound Clear into our portfolio, a device that immediately addresses that TV issue, is great for the overall hearing healthcare industry because it means people will start addressing their hearing issues sooner.”

“The fact that HyperSound Clear is programmable by a hearing professional to adjust for a patient’s specific hearing profile is especially beneficial,” added Richard Johnson, Doctor of Audiology and AuDConnex co-founder. “Furthermore, the HyperSound solution brings our member practices a new brand building opportunity; truly enhancing the patient experience. We believe patients and their families will all have something to gain from this high-fidelity TV listening solution.”

Hearing loss is a growing, widespread issue that impacts people of all ages and often carries with it serious implications for one’s health, relationships, and overall well-being. Researchers estimate that one in five Americans, and one in three people over age 65, suffer from hearing loss. Impacting over 48 million Americans, hearing loss is the third most common chronic physical condition in the United States. An estimated 360 million people worldwide suffer from some form of hearing loss, and HyperSound Clear is on the verge of offering a new way for people with hearing loss to once again enjoy home entertainment.

About AuDConnex
AuDConnex is a collaborative hearing provider network/buying group of over 300 members with operations in both the United States and Canada. Founded in 2011 by Richard Johnson, Au.D, Michael Iliff, Au.D, and Ryan Lewis, AuDConnex exists to help hearing care businesses maintain their competitive edge in practice. AuDConnex is dedicated to helping hearing care professionals simplify their practice strategy, collaborate with other like-minded practitioners, and succeed in an ever-changing and competitive marketplace. For more information on AuDConnex, please visit

About Turtle Beach Corporation
Turtle Beach Corporation ( designs leading-edge audio products for the consumer, commercial and healthcare markets. Under the Turtle Beach brand (, the Company markets a wide selection of quality gaming headsets catering to a variety of gamers’ needs and budgets, for use with video game consoles, including officially-licensed headsets for the Xbox One and PlayStation®4, as well as for personal computers and mobile/tablet devices. Under the HyperSound brand (, the Company markets pioneering directed audio solutions that have applications in digital signage and kiosks, consumer electronics and healthcare. The company’s shares are traded on the NASDAQ Exchange under the symbol: HEAR.

Forward-Looking Statements
This press release includes forward-looking information and statements within the meaning of the federal securities laws. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events. Forward looking statements are based on management’s statements containing the words “may”, “could”, “would”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, “intend” and similar expressions constitute forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Forward-looking statements are based on management’s current belief, as well as assumptions made by, and information currently available to, management.

While the Company believes that its expectations are based upon reasonable assumptions, there can be no assurances that its goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect actual results and may cause results to differ materially from those expressed in forward-looking statements made by the Company or on its behalf. Some of these factors include, but are not limited to, the substantial uncertainties inherent in acceptance of existing and future products, the difficulty of commercializing and protecting new technology, the impact of competitive products and pricing, general business and economic conditions, risks associated with the expansion of our business including the implementation of any businesses we acquire, our indebtedness, and other factors discussed in our public filings, including the risk factors included in the Company’s most recent Annual Report on Form 10-K and the Company’s other periodic reports. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the Securities and Exchange Commission, the Company any is under no obligation to publicly update or revise any forward-looking statement after the date of this release whether as a result of new information, future developments or otherwise.

Wednesday, June 24th, 2015 Uncategorized Comments Off on (HEAR) Partners With AuDConnex For Directed Audio Hearing Solution

(EGLT) Announces Launch of Specialty Pharmaceutical Sales Force

WAYNE, Pa., June 23, 2015  — Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the deployment of its specialty sales force to support the promotion of SPRIX®  (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

The sales force will focus on the top prescribing healthcare providers who prescribe pain medication. Sales representatives will begin making office visits to educate healthcare providers on SPRIX, a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level, following the completion of sales training. Promotion of OXAYDO, the first and only approved immediate-release oxycodone product formulated to discourage abuse via snorting, will begin by the end of the third quarter.

“All of the sales representatives have a track record of selling success, making this specialty pharmaceutical sales force prepared to successfully market not only SPRIX and OXAYDO, but also our Guardian™ pipeline products,” said Deanne Melloy, chief commercial officer. “SPRIX, a nasal spray NSAID providing opioid-level pain relief, is now available through SPRIX Direct our specialty pharmacy distribution program designed to make access easier for patients needing SPRIX.”

For eligible patients prescribed SPRIX, there is an automatic co-pay savings program. For more information on SPRIX, please visit or call 1-844-97-SPRIX (1-844-977-7749).

About Egalet
Egalet, a fully integrated commercial specialty pharmaceutical company, is focused on developing, manufacturing and marketing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate, and SPRIX® (ketorolac tromethamine) Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. In addition, using Egalet’s proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet’s Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full prescribing information for OXAYDO and SPRIX and additional information on Egalet can be found at

Important Safety Information for OXAYDO™ (oxycodone HCl, USP) Tablets for oral use only – CII
OXAYDO is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

OXAYDO is contraindicated in patients with respiratory depression, paralytic ileus, acute or severe bronchial asthma or hypercarbia, or known hypersensitivity to oxycodone or any components of the product.

Respiratory depression is the primary risk of OXAYDO and it must be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale, in patients with decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression.

OXAYDO contains oxycodone HCl, an opioid agonist and a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. OXAYDO can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing in situations where there is concern about an increased risk of misuse or abuse. OXAYDO may be abused by crushing, chewing, snorting or injecting the product and these practices pose a significant risk to the abuser that could result in overdose and death.

Patients receiving central nervous system depressants concomitantly with OXAYDO may exhibit an additive central nervous system depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Patients should not consume alcoholic beverages, or any medications containing alcohol while taking OXAYDO.

OXAYDO may cause severe hypotension in patients whose ability to maintain blood pressure has been compromised. OXAYDO may produce orthostatic hypotension in ambulatory patients. OXAYDO must be administered with caution in patients in circulatory shock.

Serious adverse reactions that may be associated with OXAYDO include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension and/or shock. The most common adverse reactions are nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia and somnolence.

In opioid naïve patients, start dosing OXAYDO with five to 15 mg every four to six hours as needed for pain. OXAYDO should not be given to anyone other than the individual for whom it was prescribed. Keep OXAYDO in a locked cabinet, drawer or medicine safe so that it will not be stolen.

Please see full prescribing information for OXAYDO at

Important Safety Information for SPRIX® (ketorolac tromethamine) Nasal Spray
SPRIX® is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.  Do not exceed a total combined duration of use of SPRIX and other ketorolac formulations (IM/IV or oral) of 5 days. SPRIX is not indicated for use in pediatric patients or for minor or chronic painful conditions.

SPRIX is contraindicated as follows: in patients with peptic ulcer disease or a history of GI bleeding; in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or at high risk of bleeding; for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; in patients with advanced renal impairment and those at risk for renal failure due to volume depletion; use as a prophylactic analgesic before any surgery; use in labor and delivery; use in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; and, known hypersensitivity to ketorolac, aspirin, other NSAIDs or EDTA.

SPRIX should be used with caution in patients with a prior history of ulcer disease or GI bleeding, coagulation disorders, in patients taking diuretics or ACE inhibitors, or those with compromised cardiac function.  NSAIDs can cause serious anaphylactoid reactions and serious dermatologic adverse reactions; SPRIX should be discontinued immediately in patients with allergic reactions or skin reactions.

The most common adverse reactions (incidence > 2%) in patients treated with SPRIX and occurring at a rate at least twice that of placebo are nasal discomfort, rhinalgia, increased lacrimation, throat irritation, oliguria, rash, bradycardia, decreased urine output, increased ALT and/or AST, hypertension, and rhinitis.

SPRIX is not an inhaled product. SPRIX nasal spray should be discarded within 24 hours of taking the first dose, even if the bottle still contains some medication.

Please see full prescribing information for SPRIX at

Safe Harbor
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks.  Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials; our ability to obtain regulatory approval of our product candidates; competitive factors; general market conditions; and other risks factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Tel: 917-432-9275

Tuesday, June 23rd, 2015 Uncategorized Comments Off on (EGLT) Announces Launch of Specialty Pharmaceutical Sales Force
Top Small Cap Market News